1
|
Aljaber MY, Orie NN, Raees A, Kraiem S, Al-Jaber M, Samsam W, Hamza MM, Abraham D, Kneteman NM, Beotra A, Mohamed-Ali V, Almaadheed M. Downregulation of CYP17A1 by 20-hydroxyecdysone: plasma progesterone and its vasodilatory properties. Future Sci OA 2022; 8:FSO805. [PMID: 35909994 PMCID: PMC9327640 DOI: 10.2144/fsoa-2022-0006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Accepted: 06/15/2022] [Indexed: 11/23/2022] Open
Abstract
Aim: To investigate the effect of 20-hydroxyecdysone on steroidogenic pathway genes and plasma progesterone, and its potential impact on vascular functions. Methods: Chimeric mice with humanized liver were treated with 20-hydroxyecdysone for 3 days, and hepatic steroidogenic pathway genes and plasma progesterone were measured by transcriptomics and GC–MS/MS, respectively. Direct effects on muscle and mesenteric arterioles were assessed by myography. Results: CYP17A1 was downregulated in 20-hydroxyecdysone-treated mice compared with untreated group (p = 0.04), with an insignificant increase in plasma progesterone. Progesterone caused vasorelaxation which was blocked by 60 mM KCl, but unaffected by nitric oxide synthase inhibition. Conclusion: In the short term, 20-hydroxyecdysone mediates CYP17A1 downregulation without a significant increase in plasma progesterone, which has a vasodilatory effect involving inhibition of voltage-dependent calcium channels, and the potential to enhance 20-hydroxyecdysone vasorelaxation.
Collapse
Affiliation(s)
| | - Nelson N Orie
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
- Centre of Metabolism & Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, London, NW3 2PF, UK
| | - Asmaa Raees
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
| | - Suhail Kraiem
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
| | - Mashael Al-Jaber
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
| | - Waseem Samsam
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
| | - Mostafa M Hamza
- Qatar Computing Research Institute, Hamad bin Khalifa University, Doha, 5825, Qatar
| | - David Abraham
- Centre of Metabolism & Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, London, NW3 2PF, UK
| | - Norman M Kneteman
- KMT Hepatech Inc., PhoenixBio Group, 11421 Saskatchewan Drive, Edmonton, AB, T6G 2M9, Canada
- Division of Transplantation Surgery, University of Alberta, Edmonton, Canada
| | - Alka Beotra
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
| | - Vidya Mohamed-Ali
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
- Centre of Metabolism & Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, London, NW3 2PF, UK
| | - Mohammed Almaadheed
- Anti-Doping Laboratory Qatar, Sports City Road, Doha, 27775, Qatar
- Centre of Metabolism & Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, London, NW3 2PF, UK
| |
Collapse
|
2
|
Kramer AH, Holliday K, Keenan S, Isac G, Kutsogiannis DJ, Kneteman NM, Kim P, Robertson A, Nickerson PW, Tibbles LA. Premortem anticoagulation timing and dose in donation after circulatory death: multicentre study of associations with graft function. Can J Surg 2022; 65:E474-E484. [PMID: 35902105 PMCID: PMC9343016 DOI: 10.1503/cjs.023120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/10/2021] [Indexed: 11/10/2022] Open
Abstract
Background: In controlled donation after circulatory determination of death (DCD), it is common to administer premortem heparin to potential donors. This practice remains controversial because there is limited evidence for it and there is the possibility of inducing hemorrhage. To our knowledge, no previous studies have assessed the effects of heparin timing and dose on graft function. Methods: We performed a multicentre cohort study of consecutive DCD donors and the recipients of their organs. Anticoagulation administration was considered early if given near the time of withdrawal of life-sustaining measures and late if delayed until the onset of donor hypoxemia (oxygen saturation < 70%) or hypotension (systolic blood pressure < 60 mm Hg or mean blood pressure < 50 mm Hg). The anticoagulation dose was considered high if it was 300 units/kg or greater. Results: Donor anticoagulation data were available for 301 kidney, 75 liver and 46 lung recipients. Heparin was administered in 92% of cases and was most commonly withheld in donors with cerebrovascular causes of death (p = 0.01). Administration was late in 59% and the dose was low in 27%. Among kidney recipients, there were no significant differences in need for dialysis, glomerular filtration rate over the first year after transplantation or graft survival on the basis of whether or not the donor received heparin, the timing of heparin administration or the dose of heparin. Among liver recipients, alkaline phosphatase concentrations over the first year were significantly higher among recipients who received organs from donors to whom lower doses of heparin had been administered. Conclusion: Premortem heparin is widely used in DCD cases, but there is variability in timing and dose, which was not associated with kidney outcomes in this study. Donor anticoagulation may have a greater impact in preventing biliary complications following liver transplantation.
Collapse
Affiliation(s)
- Andreas H Kramer
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Kerry Holliday
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Sean Keenan
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - George Isac
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Demetrius J Kutsogiannis
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Norman M Kneteman
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Peter Kim
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Adrian Robertson
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Peter W Nickerson
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| | - Lee Anne Tibbles
- From the Department of Critical Care Medicine, University of Calgary, Calgary, Alta. (Kramer); the Department of Clinical Neurosciences, University of Calgary, Calgary, Alta. (Kramer); the Southern Alberta Organ and Tissue Donation Program, Calgary, Alta. (Kramer); the Specialist in End-of-Life Care, Neuroprognostication and Donation (SEND) Program, Alberta Health Services (Holliday); the Division of Critical Care Medicine, Department of Medicine, University of British Columbia, Vancouver, B.C. (Keenan, Isac); BC Transplant, Vancouver, B.C. (Keenan, Isac); the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Human Organ Procurement and Exchange Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kutsogiannis); the Department of Surgery, University of Alberta, Edmonton, Alta. (Kneteman); the Alberta Transplant Institute, University of Alberta, Edmonton, Alta. (Kneteman, Tibbles); the Department of Surgery, University of British Columbia, Vancouver, B.C. (Kim); the Section of Critical Care Medicine, Department of Medicine, University of Manitoba, Winnipeg, Man. (Robertson); Transplant Manitoba, Winnipeg, Man. (Robertson, Nickerson); the Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Man. (Nickerson); the Southern Alberta Transplant Program, Calgary, Alta. (Tibbles); and the Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alta. (Tibbles)
| |
Collapse
|
3
|
Ebadi M, Dunichand-Hoedl AR, Rider E, Kneteman NM, Shapiro J, Bigam D, Dajani K, Mazurak VC, Baracos VE, Montano-Loza AJ. Higher subcutaneous adipose tissue radiodensity is associated with increased mortality in patients with cirrhosis. JHEP Rep 2022; 4:100495. [PMID: 35600667 PMCID: PMC9117882 DOI: 10.1016/j.jhepr.2022.100495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 02/24/2022] [Accepted: 03/30/2022] [Indexed: 11/21/2022] Open
Abstract
Background & Aims Association between sarcopenia and mortality in cirrhosis is well recognised; however, little is known about the clinical implications of adipose tissue radiodensity, indicative of biological features. This study aimed to determine an association between high subcutaneous adipose tissue (SAT) radiodensity and survival, compare the prevalence of high SAT radiodensity between healthy population and patients with cirrhosis, and identify an association between computed tomography (CT)-measured SAT radiodensity and histological characteristics. Methods Adult patients with cirrhosis (n = 786) and healthy donors (n = 129) with CT images taken as part of the liver transplant (LT) assessment were included. Abdominal SAT biopsies (1–2 g) were harvested from the incision site at the time of LT from 12 patients with cirrhosis. Results The majority of patients were male (67%) with a mean model for end-stage liver disease (MELD) score of 15 ± 8. SAT radiodensity above -83 HU in females (sub-distribution hazard ratio [sHR] 1.84, 95% CI 1.20–2.85, p = 0.006) and higher than -74 HU in males (sHR 1.51, 95% CI 1.05–1.18, p = 0.02) was associated with the highest mortality risk after adjusting for confounders in competing risk analysis. The frequency of high SAT radiodensity was 26% for those with cirrhosis, compared with 2% in healthy donors (p <0.001). An inverse correlation was found between SAT radiodensity and the mean cross-sectional area of SAT adipocytes (r = -0.67, p = 0.02). Shrunken, smaller adipocytes with expanded interstitial space were predominant in patients with high SAT radiodensity, whereas larger adipocytes with a thin rim of cytoplasm were observed in patients with low SAT radiodensity (744 ± 400 vs. 1,521 ± 1,035 μm2, p <0.001). Conclusion High SAT radiodensity frequently presents and is associated with a higher mortality in cirrhosis. SAT morphological rearrangement in patients with high SAT radiodensity might indicate diminished lipid stores and alterations in tissue characteristics. Lay summary Poor quality of subcutaneous adipose tissue (fat under the skin) is associated with higher mortality in patients with end-stage liver disease. Fat cells are smaller in patients with poor adipose tissue quality. Subcutaneous adipose tissue (SAT) radiodensity can be objectively measured by CT in Hounsfield units (HU). SAT radiodensity constitutes an indirect surrogate marker of adipose tissue quality. High SAT radiodensity in cirrhosis was defined as >-83 HU in females and >-74 HU in males. High SAT radiodensity presents in more than a quarter of patients with cirrhosis and is associated with higher mortality. High SAT radiodensity might indicate adipose tissue remodelling with morphological features of atrophy.
Collapse
|
4
|
Nickel KJ, Staples J, Meeberg G, Kwan PO, Gilmour S, Bigam DL, Dajani K, Shapiro AMJ, Kneteman NM, Ladak A. The Transition to Microsurgical Technique for Hepatic Artery Reconstruction in Pediatric Liver Transplantation. Plast Reconstr Surg 2021; 148:248e-257e. [PMID: 34181598 DOI: 10.1097/prs.0000000000008169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND Hepatic artery thrombosis represents a potentially fatal complication following liver transplantation. Rates of hepatic artery thrombosis are significantly higher in children, with mortality reported up to 80 percent. Microsurgical anastomosis has been shown to decrease the rate of hepatic artery thrombosis and now represents the standard of care at the authors' institution. In this article, the authors present the largest study of its type directly comparing rates of hepatic artery thrombosis with and without microsurgical reconstruction of the hepatic artery. METHODS All pediatric patients who underwent primary orthotopic liver transplantation between 1989 and 2018 were included. Patients were divided into two cohorts: standard anastomosis with loupes, and microsurgical anastomosis under the operating microscope. The authors' primary outcome was the rate of hepatic artery thrombosis. Secondary outcomes were graft survival, patient survival, retransplantation rate, requirement for intraoperative blood products, and length of stay. RESULTS Two hundred thirty-one children met criteria for inclusion. One hundred eighty cases were performed with loupe magnification and 51 cases were performed under the microscope. The hepatic artery thrombosis rate was lower, but not significantly so (p = 0.114), in the microsurgical group [n = 1 (2.0 percent)] compared with the standard cohort [n = 15 (8.3 percent)]. Survival analysis revealed a significant increase in graft survival with microsurgical anastomosis (p = 0.020), but not patient survival (p = 0.196). The retransplantation rate was significantly lower with microsurgical anastomosis (p = 0.021). CONCLUSIONS Microsurgical anastomosis was associated with a clinically important decrease in hepatic artery thrombosis compared with standard loupe anastomosis. The graft survival rate was significantly higher in the microsurgical cohort, with a reduced retransplantation rate at 1 year. On this basis, the authors recommend microsurgical hepatic artery anastomosis in cases of pediatric liver transplantation. . CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, III.
Collapse
Affiliation(s)
- Kevin J Nickel
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - John Staples
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - Glenda Meeberg
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - Peter O Kwan
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - Susan Gilmour
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - David L Bigam
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - Khaled Dajani
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - A M James Shapiro
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - Norman M Kneteman
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| | - Adil Ladak
- From the Divisions of Plastic Surgery, General and Transplant Surgery, and Pediatric Gastroenterology, University of Alberta
| |
Collapse
|
5
|
Alabi A, Xia XD, Gu HM, Wang F, Deng SJ, Yang N, Adijiang A, Douglas DN, Kneteman NM, Xue Y, Chen L, Qin S, Wang G, Zhang DW. Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis. Nat Commun 2021; 12:1889. [PMID: 33767172 PMCID: PMC7994674 DOI: 10.1038/s41467-021-22167-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 03/02/2021] [Indexed: 01/07/2023] Open
Abstract
Plasma low-density lipoprotein (LDL) is primarily cleared by LDL receptor (LDLR). LDLR can be proteolytically cleaved to release its soluble ectodomain (sLDLR) into extracellular milieu. However, the proteinase responsible for LDLR cleavage is unknown. Here we report that membrane type 1-matrix metalloproteinase (MT1-MMP) co-immunoprecipitates and co-localizes with LDLR and promotes LDLR cleavage. Plasma sLDLR and cholesterol levels are reduced while hepatic LDLR is increased in mice lacking hepatic MT1-MMP. Opposite effects are observed when MT1-MMP is overexpressed. MT1-MMP overexpression significantly increases atherosclerotic lesions, while MT1-MMP knockdown significantly reduces cholesteryl ester accumulation in the aortas of apolipoprotein E (apoE) knockout mice. Furthermore, sLDLR is associated with apoB and apoE-containing lipoproteins in mouse and human plasma. Plasma levels of sLDLR are significantly increased in subjects with high plasma LDL cholesterol levels. Thus, we demonstrate that MT1-MMP promotes ectodomain shedding of hepatic LDLR, thereby regulating plasma cholesterol levels and the development of atherosclerosis.
Collapse
Affiliation(s)
- Adekunle Alabi
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Xiao-Dan Xia
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.,Department of Orthopedics, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
| | - Hong-Mei Gu
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Faqi Wang
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Shi-Jun Deng
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Nana Yang
- Experimental Center for Medical Research, Weifang Medical University, Weifang, China
| | - Ayinuer Adijiang
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Donna N Douglas
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Norman M Kneteman
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Yazhuo Xue
- Institute of Atherosclerosis in Shandong First Medical University (Shandong Academy of Medical Sciences), Taian, China
| | - Li Chen
- Institute of Atherosclerosis in Shandong First Medical University (Shandong Academy of Medical Sciences), Taian, China
| | - Shucun Qin
- Institute of Atherosclerosis in Shandong First Medical University (Shandong Academy of Medical Sciences), Taian, China
| | - Guiqing Wang
- Department of Orthopedics, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
| | - Da-Wei Zhang
- The Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
6
|
Kramer AH, Holliday K, Keenan S, Isac G, Kutsogiannis DJ, Kneteman NM, Robertson A, Nickerson P, Tibbles LA. Donation after circulatory determination of death in western Canada: a multicentre study of donor characteristics and critical care practices. Can J Anaesth 2020; 67:521-531. [PMID: 32100271 DOI: 10.1007/s12630-020-01594-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2019] [Revised: 11/05/2019] [Accepted: 11/20/2019] [Indexed: 01/15/2023] Open
Abstract
PURPOSE Donation after circulatory determination of death (DCD) has been performed in Canada since 2006. Numerous aspects of donor management remain controversial. METHODS We performed a multicentre cohort study involving potential DCD donors in western Canada (2008-2017), as well as recipients of their organs, to describe donor characteristics and critical care practices, and their relation to one-year recipient and graft survival. RESULTS There were 257 patients in four provinces that underwent withdrawal of life-sustaining therapies (WLST) in anticipation of possible DCD. The proportion of patients that died within two hours of WLST ranged from 67% to 88% across provinces (P = 0.06), and was predicted by deeper coma (P = 0.01), loss of pupillary light or corneal reflexes (P = 0.02), and vasopressor use (P = 0.01). There were significant differences between provinces in time intervals from onset of hypotension to death (9-11 min; P = 0.02) and death to vascular cannulation (7-10 min; P < 0.001). There was inconsistency in pre-mortem heparin administration (82-96%; P = 0.03), including timing (before vs after WLST; P < 0.001) and dose (≥ 300 vs < 300 units·kg-1; P < 0.001). Donation after circulatory death provided organs for 321 kidney, 81 liver, and 50 lung transplants. One-year recipient and graft survival did not differ among provinces (range 85-90%, P = 0.45). Predictors of death or graft failure included older recipient age (odds ratio [OR] per year, 1.04; 95% confidence interval [CI],1.01 to 1.07) and male donor sex (OR, 3.35; 95% CI, 1.39 to 8.09), but not time intervals between WLST and cannulation or practices related to heparin use. CONCLUSION There is significant variability in critical care DCD practices in western Canada, but this has not resulted in significant differences in recipient or graft survival. Further research is required to guide optimal management of potential DCD donors.
Collapse
Affiliation(s)
- Andreas H Kramer
- Department of Critical Care Medicine, Foothills Medical Center, University of Calgary, 3132 Hospital Drive N.W, Calgary, AB, T2N 5A1, Canada.
- Southern Alberta Organ and Tissue Donation Program, Alberta Health Services, Calgary, AB, Canada.
| | - Kerry Holliday
- Southern Alberta Organ and Tissue Donation Program, Alberta Health Services, Calgary, AB, Canada
| | - Sean Keenan
- Division of Critical Care Medicine, University of British Columbia, Vancouver, BC, Canada
- BC Transplant, Vancouver, BC, Canada
| | - George Isac
- Division of Critical Care Medicine, University of British Columbia, Vancouver, BC, Canada
- BC Transplant, Vancouver, BC, Canada
| | - Demetrios J Kutsogiannis
- Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada
- Human Organ, Procurement, and Exchange (HOPE) Program, University of Alberta, Edmonton, AB, Canada
| | - Norman M Kneteman
- Department of Surgery, University of Alberta, Edmonton, AB, Canada
- Alberta Transplant Institute, Edmonton, AB, Canada
| | - Adrian Robertson
- Division of Critical Care Medicine, University of Manitoba, Winnipeg, MB, Canada
- Transplant Manitoba, Winnipeg, MB, Canada
| | - Peter Nickerson
- Transplant Manitoba, Winnipeg, MB, Canada
- Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
| | - Lee Anne Tibbles
- Southern Alberta Transplant Program, Calgary, AB, Canada
- Department of Medicine, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
7
|
Brahmania M, Marquez V, Kneteman NM, Bhat M, Marleau D, Wong P, Peletekian KM, Burak KW, Congly SE. Canadian liver transplant allocation for hepatocellular carcinoma. J Hepatol 2019; 71:1058-1060. [PMID: 31495534 DOI: 10.1016/j.jhep.2019.07.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Accepted: 07/17/2019] [Indexed: 12/04/2022]
Affiliation(s)
- Mayur Brahmania
- Division of Gastroenterology, Department of Medicine, and Multi Organ Transplant Unit, London Health Sciences Centre, Western University, London, Ontario, Canada
| | - Vladimir Marquez
- Division of Gastroenterology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada
| | - Norman M Kneteman
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Mamatha Bhat
- Department of Medicine, Multi-Organ Transplant Program, Toronto General Hospital, Toronto, Canada
| | - Denis Marleau
- Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
| | - Philip Wong
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Royal Victoria Hospital, Montréal, Quebec, Canada
| | - Kevork M Peletekian
- Division of Digestive Care & Endoscopy, Dalhousie University and Atlantic Multi-Organ Transplantation Program, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
| | - Kelly W Burak
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Stephen E Congly
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
| |
Collapse
|
8
|
Karvellas CJ, Taylor S, Bigam D, Kneteman NM, Shapiro AMJ, Romanovsky A, Gibney RTN, Townsend DR, Meeberg G, Özelsel T, Bishop E, Bagshaw SM. Intraoperative continuous renal replacement therapy during liver transplantation: a pilot randomized-controlled trial (INCEPTION). Can J Anaesth 2019; 66:1151-1161. [PMID: 31350701 DOI: 10.1007/s12630-019-01454-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 05/29/2019] [Accepted: 06/04/2019] [Indexed: 01/02/2023] Open
Abstract
PURPOSE To evaluate the feasibility of intraoperative continuous renal replacement therapy (IoCRRT) during liver transplantation (LT), in terms of recruitment, protocol adherence, and ascertainment of follow-up. METHODS In this pilot randomized open-label controlled trial in adults receiving LT with a Model for End-Stage Liver Disease (MELD) score ≥ 25 and preoperative acute kidney injury (RIFLE - RISK or higher) and/or estimated glomerular filtration rate < 60 mL·min-1·1.73 m-2, patients were randomized to receive IoCRRT or standard of care (SOC). Primary endpoints were feasibility and adverse events. Primary analysis was intention-to-treat (n = 32) and secondary analysis was per-protocol (n = 28). RESULTS The trial was stopped early because of slow patient accrual and inadequate funding. Sixty patients were enrolled and 32 (53%) were randomized (n = 15 IoCRRT; n = 17 SOC). Mean (standard deviation) MELD was 36 (8), 81% (n = 26) had cirrhosis; 69% (n = 22) received preoperative RRT; 66% (n = 21) received LT from the intensive care unit. Four patients (n = 2 IoCRRT, n = 2 SOC) did not receive LT post-randomization. Seven patients (41%) allocated to SOC crossed over intraoperatively to IoCRRT. Three patients were lost to follow-up at one year. No adverse events occurred related to IoCRRT. There were no differences in survival at one year (IoCRRT, 71% [n = 10/14] vs SOC, 93% [n = 14/15]; risk ratio, 0.77; 95% confidence interval, 0.54 to 1.1). In the per-protocol analysis (n = 28 received IoCRRT after randomization - n = 20 IoCRRT, n = 8 SOC), one-year survival was 92% and perioperative complications were similar between groups. Only one patient was receiving dialysis one year after LT. CONCLUSION In this pilot randomized trial, IoCRRT was feasible and safe with no difference in complications. Crossover rates were high. Despite high preoperative severity of illness, one-year survival was excellent. These data can inform the design of a larger multicentre trial. TRIAL REGISTRATION www.clinicalTrials.gov (NCT01575015); registered 12 April, 2012.
Collapse
Affiliation(s)
- Constantine J Karvellas
- Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124E Clinical Science Building, 8440-112 Street, Edmonton, AB, T6G 2B7, Canada.,Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, AB, Canada
| | - Samantha Taylor
- Department of Anesthesia and Pain Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - David Bigam
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Norman M Kneteman
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - A M James Shapiro
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Adam Romanovsky
- Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124E Clinical Science Building, 8440-112 Street, Edmonton, AB, T6G 2B7, Canada
| | - R T Noel Gibney
- Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124E Clinical Science Building, 8440-112 Street, Edmonton, AB, T6G 2B7, Canada
| | - Derek R Townsend
- Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124E Clinical Science Building, 8440-112 Street, Edmonton, AB, T6G 2B7, Canada.,Department of Anesthesia and Pain Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Glenda Meeberg
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Timur Özelsel
- Department of Anesthesia and Pain Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Edward Bishop
- Department of Anesthesia and Pain Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Sean M Bagshaw
- Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124E Clinical Science Building, 8440-112 Street, Edmonton, AB, T6G 2B7, Canada.
| |
Collapse
|
9
|
Abstract
The complete life cycle of the hepatitis C virus (HCV) can be recapitulated in vivo using immunodeficient mice that have had their livers extensively repopulated with human hepatocytes. These human liver chimeric mouse models have enabled the study of many aspects of the HCV life cycle, including antiviral interventions that have helped to shape the curative landscape that is available today. The first human liver chimeric mouse model capable of supporting the HCV life cycle was generated in SCID-uPA mice. Although other human liver chimeric mouse models have since been developed, the SCID-uPA mouse model remains one of the most robust in vivo systems available for HCV studies. This chapter reviews development, validation and application of the SCID-uPA mouse model, and discusses their potential application for studying other liver-centric diseases and pathogens and for the design and testing of vaccine candidates for the eradication of HCV.
Collapse
Affiliation(s)
- Donna N Douglas
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| | - Norman M Kneteman
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
| |
Collapse
|
10
|
Liu Q, Leslie EM, Moe B, Zhang H, Douglas DN, Kneteman NM, Le XC. Metabolism of a Phenylarsenical in Human Hepatic Cells and Identification of a New Arsenic Metabolite. Environ Sci Technol 2018; 52:1386-1392. [PMID: 29280623 DOI: 10.1021/acs.est.7b05081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Environmental contamination and human consumption of chickens could result in potential exposure to Roxarsone (3-nitro-4-hydroxyphenylarsonic acid), an organic arsenical that has been used as a chicken feed additive in many countries. However, little is known about the metabolism of Roxarsone in humans. The objective of this research was to investigate the metabolism of Roxarsone in human liver cells and to identify new arsenic metabolites of toxicological significance. Human primary hepatocytes and hepatocellular carcinoma HepG2 cells were treated with 20 or 100 μM Roxarsone. Arsenic species were characterized using a strategy of complementary chromatography and mass spectrometry. The results showed that Roxarsone was metabolized to more than 10 arsenic species in human hepatic cells. A new metabolite was identified as a thiolated Roxarsone. The 24 h IC50 values of thiolated Roxarsone for A549 lung cancer cells and T24 bladder cancer cells were 380 ± 80 and 42 ± 10 μM, respectively, more toxic than Roxarsone, whose 24 h IC50 values for A549 and T24 were 9300 ± 1600 and 6800 ± 740 μM, respectively. The identification and toxicological studies of the new arsenic metabolite are useful for understanding the fate of arsenic species and assessing the potential impact of human exposure to Roxarsone.
Collapse
Affiliation(s)
- Qingqing Liu
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta , 10-102 Clinical Sciences Building, Edmonton, Alberta, Canada T6G 2G3
| | - Elaine M Leslie
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta , 10-102 Clinical Sciences Building, Edmonton, Alberta, Canada T6G 2G3
- Department of Physiology, Faculty of Medicine and Dentistry, University of Alberta , 7-08A Medical Sciences Building, Edmonton, Alberta, Canada T6G 2H7
| | - Birget Moe
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta , 10-102 Clinical Sciences Building, Edmonton, Alberta, Canada T6G 2G3
- Alberta Centre for Toxicology, Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary , Calgary, Alberta, Canada T2N 4N1
| | - Hongquan Zhang
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta , 10-102 Clinical Sciences Building, Edmonton, Alberta, Canada T6G 2G3
| | - Donna N Douglas
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Walter C. Mackenzie Health Sciences Centre , Edmonton, Alberta, Canada T6G 2B7
| | - Norman M Kneteman
- Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Walter C. Mackenzie Health Sciences Centre , Edmonton, Alberta, Canada T6G 2B7
| | - X Chris Le
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta , 10-102 Clinical Sciences Building, Edmonton, Alberta, Canada T6G 2G3
| |
Collapse
|
11
|
Yang ASP, O'Neill MT, Jennison C, Lopaticki S, Allison CC, Armistead JS, Erickson SM, Rogers KL, Ellisdon AM, Whisstock JC, Tweedell RE, Dinglasan RR, Douglas DN, Kneteman NM, Boddey JA. Cell Traversal Activity Is Important for Plasmodium falciparum Liver Infection in Humanized Mice. Cell Rep 2017; 18:3105-3116. [PMID: 28355563 DOI: 10.1016/j.celrep.2017.03.017] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2016] [Revised: 02/06/2017] [Accepted: 03/02/2017] [Indexed: 01/29/2023] Open
Abstract
Malaria sporozoites are deposited into the skin by mosquitoes and infect hepatocytes. The molecular basis of how Plasmodium falciparum sporozoites migrate through host cells is poorly understood, and direct evidence of its importance in vivo is lacking. Here, we generated traversal-deficient sporozoites by genetic disruption of sporozoite microneme protein essential for cell traversal (PfSPECT) or perforin-like protein 1 (PfPLP1). Loss of either gene did not affect P. falciparum growth in erythrocytes, in contrast with a previous report that PfPLP1 is essential for merozoite egress. However, although traversal-deficient sporozoites could invade hepatocytes in vitro, they could not establish normal liver infection in humanized mice. This is in contrast with NF54 sporozoites, which infected the humanized mice and developed into exoerythrocytic forms. This study demonstrates that SPECT and perforin-like protein 1 (PLP1) are critical for transcellular migration by P. falciparum sporozoites and demonstrates the importance of cell traversal for liver infection by this human pathogen.
Collapse
Affiliation(s)
- Annie S P Yang
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia
| | - Matthew T O'Neill
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia
| | - Charlie Jennison
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia
| | - Sash Lopaticki
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia
| | - Cody C Allison
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia
| | - Jennifer S Armistead
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia
| | - Sara M Erickson
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia
| | - Kelly L Rogers
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia
| | - Andrew M Ellisdon
- Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton 3800, VIC, Australia; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton 3800, VIC, Australia
| | - James C Whisstock
- Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton 3800, VIC, Australia; Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton 3800, VIC, Australia
| | - Rebecca E Tweedell
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Rhoel R Dinglasan
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Donna N Douglas
- Department of Surgery, University of Alberta, Edmonton, AB T6G 2E1, Canada
| | - Norman M Kneteman
- Department of Surgery, University of Alberta, Edmonton, AB T6G 2E1, Canada
| | - Justin A Boddey
- Division of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville 3052, VIC, Australia.
| |
Collapse
|
12
|
Shapiro AM, Hao E, Rajotte RV, Kneteman NM. High Yield of Rodent Islets with Intraductal Collagenase and Stationary Digestion—A Comparison with Standard Technique. Cell Transplant 2017; 5:631-8. [PMID: 8951221 DOI: 10.1177/096368979600500606] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Intraductal distention of the pancreas with collagenase followed by stationary warm incubation improves the recovery of islets of Langerhans in the rat, but controlled studies are needed for valid comparison with standard isolation methods. We have modified Gotoh's technique of stationary digestion for high-yield isolation in the rat (Stationary). The method is subjected herein to rigorous blinded comparison with the standard chopped tissue (Chopped) technique, based on Lacy et al., as performed in our laboratory for over 10 yr. Islet recovery was determined by a single observer ‘blinded’ to the method of isolation used, and only intact islets of diameter ≥ 100 μm were included. Stationary gave 719 ± 114 islets per pancreas (mean ± SD, n = 21 isolations) vs. 487.5 ± 69 for Chopped (n = 36 isolations), a 47.5% increment in yield (p < 0.0001). In vitro islet perifusion showed no statistical difference in stimulation index (SI) or stimulated area under the curve (SAUC) between the two methods, but Stationary showed a trend towards improved phase II insulin release. In vivo function was assessed by isogeneic transplantation of 2,000 islets beneath the renal capsule of streptozotocin diabetic recipients (65 mg/kg Sigma); Stationary recipients (n = 7) became normoglycemic (≤ 8 mmol/L) by 3.3 ± 4.8 days vs. 1.6 ± 1.5 days for Chopped recipients (p = 0.4 ns, mean ± SEM). IVGTT performed at 1 mo posttransplant gave K-values for Stationary of 2.64 ± 0.8 vs. 2.62 ± 0.8 for Chopped (mean ± SD, p = 0.9 ns, n = 6, unpaired t-test), which were not distinguishable from normal control rats (2.59 ± 0.8) (p = 0.9 ns, n = 10). Graft function remained stable until graft bearing nephrectomy induced hyperglycemia uniformly within 1 day. Graft histology showed a healthy well-preserved structure on light microscopy, with well-granulated beta cells on EM. Economic costs of rat, collagenase, and Ficoll were 26% ($50.82) lower per recipient for Stationary. We conclude that modified stationary digestion significantly improves islet recovery with excellent in vitro and in vivo function, and is cost effective.
Collapse
Affiliation(s)
- A M Shapiro
- Department of Surgery, University of Alberta, Edmonton, Canada
| | | | | | | |
Collapse
|
13
|
Yang ASP, Lopaticki S, O'Neill MT, Erickson SM, Douglas DN, Kneteman NM, Boddey JA. AMA1 and MAEBL are important for Plasmodium falciparum sporozoite infection of the liver. Cell Microbiol 2017; 19. [PMID: 28371168 DOI: 10.1111/cmi.12745] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 03/23/2017] [Accepted: 03/28/2017] [Indexed: 12/20/2022]
Abstract
The malaria sporozoite injected by a mosquito migrates to the liver by traversing host cells. The sporozoite also traverses hepatocytes before invading a terminal hepatocyte and developing into exoerythrocytic forms. Hepatocyte infection is critical for parasite development into merozoites that infect erythrocytes, and the sporozoite is thus an important target for antimalarial intervention. Here, we investigated two abundant sporozoite proteins of the most virulent malaria parasite Plasmodium falciparum and show that they play important roles during cell traversal and invasion of human hepatocytes. Incubation of P. falciparum sporozoites with R1 peptide, an inhibitor of apical merozoite antigen 1 (AMA1) that blocks merozoite invasion of erythrocytes, strongly reduced cell traversal activity. Consistent with its inhibitory effect on merozoites, R1 peptide also reduced sporozoite entry into human hepatocytes. The strong but incomplete inhibition prompted us to study the AMA-like protein, merozoite apical erythrocyte-binding ligand (MAEBL). MAEBL-deficient P. falciparum sporozoites were severely attenuated for cell traversal activity and hepatocyte entry in vitro and for liver infection in humanized chimeric liver mice. This study shows that AMA1 and MAEBL are important for P. falciparum sporozoites to perform typical functions necessary for infection of human hepatocytes. These two proteins therefore have important roles during infection at distinct points in the life cycle, including the blood, mosquito, and liver stages.
Collapse
Affiliation(s)
- Annie S P Yang
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.,Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
| | - Sash Lopaticki
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - Matthew T O'Neill
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
| | - Sara M Erickson
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.,Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
| | - Donna N Douglas
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Norman M Kneteman
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Justin A Boddey
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.,Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
| |
Collapse
|
14
|
Gonzalez-Aldaco K, Rebello Pinho JR, Panduro A, Martinez-Lopez E, Gleyzer K, Fierro N, Roman S, Kneteman NM, Marotta PJ, Al-Judaibi B. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. Ann Hepatol 2017; 16:236-436. [PMID: 28233743 DOI: 10.5604/16652681.1231582] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The prevalence of two functional polymorphisms (rs1127354 and rs7270101) of the inosine triphosphatase (ITPA) gene associated with ribavirin-induced hemolytic anemia (RIHA) during antiviral therapy for hepatitis C virus (HCV) infection varies by ethnicity. In Mexico, the distribution of these polymorphisms among Native Amerindians (NA) and admixed population (Mestizos) is unknown. This study aimed to determine the prevalence of the ITPA polymorphisms among healthy NA and Mestizos, as well as in HCV patients from West Mexico. MATERIAL AND METHODS In a cross-sectional study, 600 unrelated subjects (322 Mestizos, 100 NA, and 178 treatment-naïve, HCV-infected Mestizos patients) were enrolled. A medical history was registered. ITPA genotype was determined by Real-Time PCR. Fst-values and genetic relatedness between study and reference populations were assessed. RESULTS The frequency of the risk genotypes rs1127354CC and rs7270101AA was higher among NA (98-100%) than in Mestizos (87-92.9%), (p &lt; 0.05). The NA presented the highest prevalence of the rs1127354CC genotype reported worldwide. The Fst-values revealed a genetic relatedness among Mexican NA, South Americans and African populations (p &gt; 0.05). The frequency of the predicted risk for RIHA was higher among NA (98%) than in Mestizos (80.5%) and HCV-infected patients (81.5%) (p &lt; 0 .01). The CC/AA alleles were associated with lower values of total bilirubin, aspartate/alanine aminotransferases, and aspartate-to-platelet-ratio-index score among HCV-patients. CONCLUSION A high prevalence of the ITPA polymorphisms associated with RIHA was found in Mexican NA. These polymorphisms could be a useful tool for evaluating potential adverse effects and the risk or benefit of antiviral therapy in Mexicans and other admixed populations.
Collapse
Affiliation(s)
- Karina Gonzalez-Aldaco
- Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
| | | | - Arturo Panduro
- Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
| | - Erika Martinez-Lopez
- Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
| | - Ketti Gleyzer
- Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
| | - Nora Fierro
- Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
| | - Sonia Roman
- Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
| | - Norman M Kneteman
- Division of Surgery (Transplantation), University of Alberta, Edmonton, Canada
| | - Paul J Marotta
- Division of Surgery (Transplantation), University of Alberta, Edmonton, Canada
| | - Bandar Al-Judaibi
- Division of Surgery (Transplantation), University of Alberta, Edmonton, Canada
| |
Collapse
|
15
|
Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SKH. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology 2016; 64:1922-1933. [PMID: 27641232 PMCID: PMC5115987 DOI: 10.1002/hep.28850] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 08/16/2016] [Accepted: 08/23/2016] [Indexed: 01/12/2023]
Abstract
UNLABELLED Direct-acting antivirals (DAAs) have led to a high cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this still leaves a large number of treatment failures secondary to the emergence of resistance-associated variants (RAVs). To increase the barrier to resistance, a complementary strategy is to use neutralizing human monoclonal antibodies (HMAbs) to prevent acute infection. However, earlier efforts with the selected antibodies led to RAVs in animal and clinical studies. Therefore, we identified an HMAb that is less likely to elicit RAVs for affinity maturation to increase potency and, more important, breadth of protection. Selected matured antibodies show improved affinity and neutralization against a panel of diverse HCV isolates. Structural and modeling studies reveal that the affinity-matured HMAb mediates virus neutralization, in part, by inducing conformational change to the targeted epitope, and that the maturated light chain is responsible for the improved affinity and breadth of protection. A matured HMAb protected humanized mice when challenged with an infectious HCV human serum inoculum for a prolonged period. However, a single mouse experienced breakthrough infection after 63 days when the serum HMAb concentration dropped by several logs; sequence analysis revealed no viral escape mutation. CONCLUSION The findings suggest that a single broadly neutralizing antibody can prevent acute HCV infection without inducing RAVs and may complement DAAs to reduce the emergence of RAVs. (Hepatology 2016;64:1922-1933).
Collapse
Affiliation(s)
- Zhen-Yong Keck
- Department of Pathology, Stanford University School of Medicine, Stanford, California, 94305, USA
| | - Yong Wang
- Department of Pathology, Stanford University School of Medicine, Stanford, California, 94305, USA
| | - Patrick Lau
- Department of Pathology, Stanford University School of Medicine, Stanford, California, 94305, USA
| | - Garry Lund
- KMT Hepatech, Inc., Edmonton, Alberta, Canada
| | - Sneha Rangarajan
- University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland 20850, USA,Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland 20742, USA
| | - Catherine Fauvelle
- Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France,Université de Strasbourg, 67000 Strasbourg, France
| | - Grant C. Liao
- Integrated BioTherapeutics, Inc., Gaithersburg, Maryland, USA
| | | | | | - M. Javad Aman
- Integrated BioTherapeutics, Inc., Gaithersburg, Maryland, USA
| | - Brian G. Pierce
- University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland 20850, USA
| | - Thomas R. Fuerst
- University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland 20850, USA
| | - Justin R. Bailey
- Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Thomas F. Baumert
- Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France,Université de Strasbourg, 67000 Strasbourg, France,Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, Institut Hopitalo-universitaire (IHU), 67000 Strasbourg, France
| | - Roy A. Mariuzza
- University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland 20850, USA,Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, Maryland 20742, USA
| | - Norman M. Kneteman
- Departments of Surgery and Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - Steven K. H. Foung
- Department of Pathology, Stanford University School of Medicine, Stanford, California, 94305, USA,Corresponding Author: Address: Stanford Blood Center, 3373 Hillview Avenue, Palo Alto, CA 94304; Telephone: 650-723-6481;
| |
Collapse
|
16
|
Wu C, Zhang HF, Gupta N, Alshareef A, Wang Q, Huang YH, Lewis JT, Douglas DN, Kneteman NM, Lai R. A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. J Hematol Oncol 2016; 9:120. [PMID: 27821172 PMCID: PMC5100098 DOI: 10.1186/s13045-016-0349-z] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 10/28/2016] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND We have previously described the existence of two phenotypically distinct cell subsets in ALK-positive anaplastic large cell lymphoma (ALK + ALCL) based on their differential responsiveness to a Sox2 reporter (SRR2), with reporter-responsive (RR) cells being more tumorigenic and chemoresistant than reporter-unresponsive (RU) cells. However, the regulator(s) of RU/RR dichotomy are not identified. In this study, we aim to delineate the key regulator(s) of RU/RR dichotomy. METHODS JASPER motif match analysis was used to identify the putative factors binding to SRR2 sequence. SRR2 probe pull-down assay and quantitate real-time PCR were performed to analyze the regulation of Sox2 transcriptional activity by MYC. Methylcellulose colony formation assay, chemoresistance to doxorubicin and mouse xenograft study were performed to investigate the biological functions of MYC. PCR array and western blotting were executed to study related signaling pathways that regulate MYC expression. Immunofluorescence and immunohistochemistry assay were initiated to evaluate the expression of MYC and its correlation with its regulator by chi-square test analysis in human primary tumor cells. RESULTS We identified MYC as a potential regulator of RU/RR dichotomy. In support of its role, MYC was highly expressed in RR cells compared to RU cells, and inhibition of MYC substantially decreased the Sox2/SRR2 binding, Sox2 transcriptional activity, chemoresistance, and methylcellulose colony formation. In contrast, enforced expression of MYC in RU cells conferred the RR phenotype. The Wnt/β-catenin pathway, a positive regulator of MYC, was highly active in RR but not RU cells. While inhibition of this pathway in RR cells substantially decreased MYC expression and SRR2 reporter activity, experimental activation of this pathway led to the opposite effects in RU cells. Collectively, our results support a model in which a positive feedback loop involving Wnt/β-catenin/MYC and Sox2 contributes to the RR phenotype. In a mouse xenograft model, RU cells stably transfected with MYC showed upregulation of the Wnt/β-catenin/MYC/Sox2 axis and increased tumorigenecity. Correlating with these findings, there was a significant correlation between the expression of active β-catenin and MYC in ALK + ALCL primary tumor cells. CONCLUSIONS A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subset in ALK + ALCL.
Collapse
Affiliation(s)
- Chengsheng Wu
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
| | - Hai-Feng Zhang
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, China
| | - Nidhi Gupta
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
| | - Abdulraheem Alshareef
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
| | - Qian Wang
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
| | - Yung-Hsing Huang
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
| | - Jamie T. Lewis
- Department of Surgery, University of Alberta, Edmonton, Alberta Canada
| | - Donna N. Douglas
- Department of Surgery, University of Alberta, Edmonton, Alberta Canada
| | | | - Raymond Lai
- Department of Laboratory Medicine and Pathology, 5142J Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, Alberta T6G 1Z2 Canada
- Department of Oncology, University of Alberta, Edmonton, Alberta Canada
- DynaLIFEDX Medical Laboratories, Edmonton, Alberta Canada
| |
Collapse
|
17
|
Jung K, Gupta N, Wang P, Lewis JT, Gopal K, Wu F, Ye X, Alshareef A, Abdulkarim BS, Douglas DN, Kneteman NM, Lai R. Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter. Oncotarget 2016; 6:10366-73. [PMID: 25868977 PMCID: PMC4496361 DOI: 10.18632/oncotarget.3590] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Accepted: 02/17/2015] [Indexed: 12/18/2022] Open
Abstract
We have recently described a novel phenotypic dichotomy within estrogen receptor-positive breast cancer cells; the cell subset responsive to a Sox2 regulatory region (SRR2) reporter (RR cells) are significantly more tumorigenic than the reporter unresponsive (RU) cells. Here, we report that a similar phenomenon also exists in triple negative breast cancer (TNBC), with RR cells more tumorigenic than RU cells. First, examination of all 3 TNBC cell lines stably infected with the SRR2 reporter revealed the presence of a cell subset exhibiting reporter activity. Second, RU and RR cells purified by flow cytometry showed that RR cells expressed higher levels of CD44, generated more spheres in a limiting dilution mammosphere formation assay, and formed larger and more complex structures in Matrigel. Third, within the CD44High/CD24− tumor-initiating cell population derived from MDA-MB-231, RR cells were significantly more tumorigenic than RU cells in an in vivo SCID/Beige xenograft mouse model. Examination of 4 TNBC tumors from patients also revealed the presence of a RR cell subset, ranging from 1.1-3.8%. To conclude, we described a novel phenotypic heterogeneity within TNBC, and the SRR2 reporter responsiveness is a useful marker for identifying a highly tumorigenic cell subset within the CD44High/CD24−tumor-initiating cell population.
Collapse
Affiliation(s)
- Karen Jung
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
| | - Nidhi Gupta
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Peng Wang
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Jamie T Lewis
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Keshav Gopal
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Fang Wu
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Xiaoxia Ye
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | - Abdulraheem Alshareef
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
| | | | - Donna N Douglas
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Norman M Kneteman
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Raymond Lai
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.,Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.,DynaLIFE Dx Medical Laboratories, Edmonton, Alberta, Canada
| |
Collapse
|
18
|
Cardoso FS, Bagshaw SM, Abraldes JG, Kneteman NM, Meeberg G, Fidalgo P, Karvellas CJ. Comorbidities have a limited impact on post-transplant survival in carefully selected cirrhotic patients: a population-based cohort study. Ann Hepatol 2016; 14:505-14. [PMID: 26019037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Improving estimation of long-term survival of patients with end-stage liver disease after orthotopic liver transplantation (OLT) would optimize decisions on eligibility for transplant. We aimed to externally validate previously derived Charlson Comorbity Index for OLT (CCI-OLT); subsequently, we developed a new model to predict 5-year mortality after transplant. MATERIAL AND METHODS This single center retrospective cohort study included 524 consecutive adult cirrhotic patients who underwent OLT in 2002-2012. External validation of CCI-OLT used Kaplan-Meier method. Derivation of the new predictive model used Cox proportional hazards regression. RESULTS One-, 3-, and 5-year cumulative survival after OLT was 89%, 80%, and 73%, respectively. CCI-OLT was not associated with 5-year mortality after transplant (P = 0.34). We derived and internally validated a new predictive model of 5-year mortality after OLT based on six pre-transplant characteristics of patients: age, body mass index, hepatitis C, hepatic encephalopathy, intensive care unit stay at transplant, and live donor (C-index = 0.64). We further developed a nomogram to estimate individual probability of 1-, 3-, and 5-year survival after OLT. CONCLUSIONS In our cohort, CCI-OLT was not associated with survival following transplant. The new predictive model discriminative capacity was only modest, suggesting that pre-transplant characteristics are of limited value in predicting post-transplant outcomes in thoroughly selected patients.
Collapse
Affiliation(s)
- Filipe S Cardoso
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Sean M Bagshaw
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Juan G Abraldes
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Norman M Kneteman
- Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Glenda Meeberg
- Liver Transplant Program, Alberta Health Services, Edmonton, Alberta, Canada
| | - Pedro Fidalgo
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Constantine J Karvellas
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Division of Gastroenterology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
19
|
Douglas DN, Pu CH, Lewis JT, Bhat R, Anwar-Mohamed A, Logan M, Lund G, Addison WR, Lehner R, Kneteman NM. Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus. J Biol Chem 2015; 291:1974-1990. [PMID: 26627833 DOI: 10.1074/jbc.m115.674861] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Indexed: 12/11/2022] Open
Abstract
Cytopathic effects are currently believed to contribute to hepatitis C virus (HCV)-induced liver injury and are readily observed in Huh7.5 cells infected with the JFH-1 HCV strain, manifesting as apoptosis highly correlated with growth arrest. Reactive oxygen species, which are induced by HCV infection, have recently emerged as activators of AMP-activated protein kinase. The net effect is ATP conservation via on/off switching of metabolic pathways that produce/consume ATP. Depending on the scenario, this can have either pro-survival or pro-apoptotic effects. We demonstrate reactive oxygen species-mediated activation of AMP-activated kinase in Huh7.5 cells during HCV (JFH-1)-induced growth arrest. Metabolic labeling experiments provided direct evidence that lipid synthesis is attenuated, and β-oxidation is enhanced in these cells. A striking increase in nuclear peroxisome proliferator-activated receptor α, which plays a dominant role in the expression of β-oxidation genes after ligand-induced activation, was also observed, and we provide evidence that peroxisome proliferator-activated receptor α is constitutively activated in these cells. The combination of attenuated lipid synthesis and enhanced β-oxidation is not conducive to lipid accumulation, yet cellular lipids still accumulated during this stage of infection. Notably, the serum in the culture media was the only available source for polyunsaturated fatty acids, which were elevated (2-fold) in the infected cells, implicating altered lipid import/export pathways in these cells. This study also provided the first in vivo evidence for enhanced β-oxidation during HCV infection because HCV-infected SCID/Alb-uPA mice accumulated higher plasma ketones while fasting than did control mice. Overall, this study highlights the reprogramming of hepatocellular lipid metabolism and bioenergetics during HCV infection, which are predicted to impact both the HCV life cycle and pathogenesis.
Collapse
Affiliation(s)
- Donna N Douglas
- From the Departments of Surgery,; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
| | - Christopher Hao Pu
- From the Departments of Surgery,; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - Jamie T Lewis
- From the Departments of Surgery,; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | | | | | - Michael Logan
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada; Medical Microbiology and Immunology
| | | | - William R Addison
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada; Medical Microbiology and Immunology
| | | | - Norman M Kneteman
- From the Departments of Surgery,; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| |
Collapse
|
20
|
Wu C, Molavi O, Zhang H, Gupta N, Alshareef A, Bone KM, Gopal K, Wu F, Lewis JT, Douglas DN, Kneteman NM, Lai R. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood 2015; 126:336-45. [PMID: 25921060 DOI: 10.1182/blood-2014-10-603738] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Accepted: 04/24/2015] [Indexed: 02/05/2023] Open
Abstract
The tumorigenicity of most cases of ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL) is driven by the oncogenic fusion protein NPM-ALK in a STAT3-dependent manner. Because it has been shown that STAT3 can be inhibited by STAT1 in some experimental models, we hypothesized that the STAT1 signaling pathway is defective in ALK+ ALCL, thereby leaving the STAT3 signaling unchecked. Compared with normal T cells, ALK+ ALCL tumors consistently expressed a low level of STAT1. Inhibition of the ubiquitin-proteasome pathway appreciably increased STAT1 expression in ALK+ ALCL cells. Furthermore, we found evidence that NPM-ALK binds to and phosphorylates STAT1, thereby promoting its proteasomal degradation in a STAT3-dependent manner. If restored, STAT1 is functionally intact in ALK+ ALCL cells, because it effectively upregulated interferon-γ, induced apoptosis/cell-cycle arrest, potentiated the inhibitory effects of doxorubicin, and suppressed tumor growth in vivo. STAT1 interfered with the STAT3 signaling by decreasing STAT3 transcriptional activity/DNA binding and its homodimerization. The importance of the STAT1/STAT3 functional interaction was further highlighted by the observation that short interfering RNA knockdown of STAT1 significantly decreased apoptosis induced by STAT3 inhibition. Thus, STAT1 is a tumor suppressor in ALK+ ALCL. Phosphorylation and downregulation of STAT1 by NPM-ALK represent other mechanisms by which this oncogenic tyrosine kinase promotes tumorigenesis.
Collapse
MESH Headings
- Anaplastic Lymphoma Kinase
- Animals
- Apoptosis
- Blotting, Western
- Case-Control Studies
- Cell Proliferation
- Cell Transformation, Neoplastic
- Down-Regulation
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunoenzyme Techniques
- Interferon-gamma
- Lymphoma, Large-Cell, Anaplastic/genetics
- Lymphoma, Large-Cell, Anaplastic/metabolism
- Lymphoma, Large-Cell, Anaplastic/pathology
- Mice
- Mice, SCID
- Phosphorylation
- Proteasome Endopeptidase Complex/metabolism
- Protein-Tyrosine Kinases/genetics
- Protein-Tyrosine Kinases/metabolism
- RNA, Small Interfering/genetics
- Receptor Protein-Tyrosine Kinases/metabolism
- STAT1 Transcription Factor/antagonists & inhibitors
- STAT1 Transcription Factor/genetics
- STAT1 Transcription Factor/metabolism
- STAT3 Transcription Factor/antagonists & inhibitors
- STAT3 Transcription Factor/genetics
- STAT3 Transcription Factor/metabolism
- Signal Transduction
- Tumor Cells, Cultured
- Ubiquitin/metabolism
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Chengsheng Wu
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | - Ommoleila Molavi
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; Faculty of Pharmacy, Tabriz University of Medical Science, Tabriz, East Azerbaijan Province, Iran
| | - Haifeng Zhang
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, Guangdong Province, China
| | - Nidhi Gupta
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | - Abdulraheem Alshareef
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | - Kathleen M Bone
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | - Keshav Gopal
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | - Fang Wu
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | | | | | | | - Raymond Lai
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; Department of Oncology, University of Alberta, Edmonton, AB, Canada; and DynaLIFE Dx Medical Laboratories, Edmonton, AB, Canada
| |
Collapse
|
21
|
Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015; 62:158-65. [PMID: 25777590 DOI: 10.1002/hep.27787] [Citation(s) in RCA: 197] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 03/10/2015] [Indexed: 01/10/2023]
Abstract
UNLABELLED The selection of liver transplantation (LT) candidates with hepatocellular carcinoma (HCC) is currently validated based on Milan criteria. The use of extended criteria has remained a matter of debate, mainly because of the absence of prospective validation. The present prospective study recruited patients according to the previously proposed total tumor volume (TTV; ≤115 cm(3) )/alpha-fetoprotein (AFP; ≤400 ng/mL) score. Patients with AFP >400 ng/mL were excluded, and, as such, the Milan group was modified to include only patients with AFP <400 ng/mL; these patients were compared to patients beyond Milan, but within TTV/AFP. From January 2007 to March 2013, 233 patients with HCC were listed for LT. Of them, 195 patients were within Milan and 38 beyond Milan, but within TTV/AFP. The average follow-up from listing was 33.9 ± 24.9 months. Risk of dropout was higher for patients beyond Milan, but within TTV/AFP (16 of 38; 42.1%), than for those within Milan (49 of 195 [25.1%]; P = 0.033). In parallel, intent-to-treat survival from listing was lower in patients beyond Milan (53.8% vs. 71.6% at 4 years; P < 0.001). After a median waiting time of 8 months, 166 patients were transplanted, 134 within Milan criteria, and 32 beyond Milan but within TTV/AFP. They demonstrated acceptable and similar recurrence rates (4.5% vs. 9.4%; P = 0.138) and post-transplant survivals (78.7% vs. 74.6% at 4 years; P = 0.932). CONCLUSION Based on the present prospective study, HCC LT candidate selection could be expanded to the TTV (≤115 cm(3) )/AFP (≤400 ng/mL) criteria in centers with at least 8-month waiting time. An increased risk of dropout on the waiting list can be expected, but with equivalent and satisfactory post-transplant survival.
Collapse
Affiliation(s)
- Christian Toso
- Divisions of Transplant and Abdominal Surgery, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland
| | - Glenda Meeberg
- Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Roberto Hernandez-Alejandro
- Multi-Organ Transplant Program, London Health Sciences Center, The University of Western Ontario, London, Ontario, Canada
| | - Jean-François Dufour
- University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland
| | - Paul Marotta
- Multi-Organ Transplant Program, London Health Sciences Center, The University of Western Ontario, London, Ontario, Canada
| | - Pietro Majno
- Divisions of Transplant and Abdominal Surgery, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland
| | - Norman M Kneteman
- Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
22
|
Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ. Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada. Can J Gastroenterol Hepatol 2015:16942. [PMID: 26076400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
|
23
|
Douglas DN, Kneteman NM. Generation of improved mouse models for the study of hepatitis C virus. Eur J Pharmacol 2015; 759:313-25. [PMID: 25814250 DOI: 10.1016/j.ejphar.2015.03.022] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Revised: 03/06/2015] [Accepted: 03/12/2015] [Indexed: 12/15/2022]
Abstract
Approximately 3% of the world׳s population suffers from chronic infections with hepatitis C virus (HCV). Although current treatment regimes are capable of effectively eradicating HCV infection from these patients, the cost of these combinations of direct-acting antivirals are prohibitive. Approximately 80% of untreated chronic HCV carriers will be at high risk for developing severe liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma. A vaccine is urgently needed to lessen this global burden. Besides humans, HCV infection can be experimentally transmitted to chimpanzees, and this is the best model for studies of HCV infection and related innate and adaptive immune responses. Although the chimpanzee model yielded valuable insight, limited availability, high cost and ethical considerations limit their utility. The only small animal models of robust HCV infection are highly immunodeficient mice with human chimeric livers. However, these mice cannot be used to study adaptive immune responses and therefore a more relevant animal model is needed to assist in vaccine development. Novel strains of immunodeficient mice have been developed that allow for the engraftment of human hepatopoietic stem cells, as well as functional human lymphoid cells and tissues, effectively creating human immune systems in otherwise immunodeficient mice. These humanized mice are rapidly emerging as pre-clinical bridges for numerous pathogens that, like HCV, only cause infectious disease in humans. This review highlights the potential these new models have for changing the current landscape for HCV research and vaccine development.
Collapse
Affiliation(s)
- Donna N Douglas
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada T6G 2E1; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada T6G 2E1.
| | - Norman M Kneteman
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada T6G 2E1; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada T6G 2E1; KMT Hepatech Inc., Edmonton, Alberta, Canada T6G 2M9
| |
Collapse
|
24
|
Roggenbeck BA, Carew MW, Charrois GJ, Douglas DN, Kneteman NM, Lu X, Le XC, Leslie EM. Characterization of arsenic hepatobiliary transport using sandwich-cultured human hepatocytes. Toxicol Sci 2015; 145:307-20. [PMID: 25752797 DOI: 10.1093/toxsci/kfv051] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Arsenic is a proven human carcinogen and is associated with a myriad of other adverse health effects. This metalloid is methylated in human liver to monomethylarsonic acid (MMA(V)), monomethylarsonous acid (MMA(III)), dimethylarsinic acid (DMA(V)), and dimethylarsinous acid (DMA(III)) and eliminated predominantly in urine. Hepatic basolateral transport of arsenic species is ultimately critical for urinary elimination; however, these pathways are not fully elucidated in humans. A potentially important human hepatic basolateral transporter is the ATP-binding cassette (ABC) transporter multidrug resistance protein 4 (MRP4/ABCC4) that in vitro is a high-affinity transporter of DMA(V) and the diglutathione conjugate of MMA(III) [MMA(GS)(2)]. In rats, the related canalicular transporter Mrp2/Abcc2 is required for biliary excretion of arsenic as As(GS)(3) and MMA(GS)(2). The current study used sandwich cultured human hepatocytes (SCHH) as a physiological model of human arsenic hepatobiliary transport. Arsenic efflux was detected only across the basolateral membrane for 9 out of 14 SCHH preparations, 5 had both basolateral and canalicular efflux. Basolateral transport of arsenic was temperature- and GSH-dependent and inhibited by the MRP inhibitor MK-571. Canalicular efflux was completely lost after GSH depletion suggesting MRP2-dependence. Treatment of SCHH with As(III) (0.1-1 µM) dose-dependently increased MRP2 and MRP4 levels, but not MRP1, MRP6, or aquaglyceroporin 9. Treatment of SCHH with oltipraz (Nrf2 activator) increased MRP4 levels and basolateral efflux of arsenic. In contrast, oltipraz increased MRP2 levels without increasing biliary excretion. These results suggest arsenic basolateral transport prevails over biliary excretion and is mediated at least in part by MRPs, most likely including MRP4.
Collapse
Affiliation(s)
- Barbara A Roggenbeck
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7 *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - Michael W Carew
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7 *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - Gregory J Charrois
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - Donna N Douglas
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - Norman M Kneteman
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - Xiufen Lu
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - X Chris Le
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| | - Elaine M Leslie
- *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7 *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7 *Department of Physiology, Membrane Protein Disease Research Group, Department of Laboratory Medicine and Pathology, and Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
| |
Collapse
|
25
|
Andres A, Livingstone S, Kin T, Campbell PM, Senior PA, Kneteman NM, Bigam D, Shapiro AMJ. Islet-after-failed-pancreas and pancreas-after-failed islet transplantation: Two complementary rescue strategies to control diabetes. Islets 2015; 7:e1126036. [PMID: 26854597 PMCID: PMC4878259 DOI: 10.1080/19382014.2015.1126036] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
For selected patients with type 1 diabetes, β-cell replacement is the treatment of choice, either by islet transplantation (ITX) or whole pancreas transplantation (PTX). When either modality fails, current practice is to consider retransplantation, or return to exogenous insulin. We investigate outcomes with PTX after failed ITX (PAI), and ITX after failed PTX (IAP). All patients receiving PAI or IAP at a single institution were identified. Donor and recipient variables were documented, including transplant outcomes analyzed for insulin requirement and metabolic control. Five subjects were listed for PAI, and 2 received transplants. Of the 4 listed for IAP, 3 have received transplants. The mean waitlist time was 4.5 ± 4.1 y for PAI and 0.35 ±0 .4 y for IAP (p = 0.08). Metabolic control was excellent after PAI, with 2/2 insulin-independent. After IAP, 1/2 achieved insulin independence and good metabolic control after 2 islet infusions. The third could not receive 2(nd) infusion and presented c-peptide levels < 0.1 nmol/L. Both strategies are feasible. The outcomes after PAI in our center must be offset by much longer waitlist time due to the sensitization status of these patients. Data from multicentre experience will allow more robust comparative outcomes to be made, the current observations being restricted to a limited patient set.
Collapse
Affiliation(s)
- Axel Andres
- Department of Surgery; University of Alberta; Edmonton, Alberta, Canada
- Correspondence to: Axel Andres;
| | - Scott Livingstone
- Department of Surgery; University of Alberta; Edmonton, Alberta, Canada
| | - Tatsuya Kin
- Department of Surgery; University of Alberta; Edmonton, Alberta, Canada
| | | | - Peter A Senior
- Department of Medicine; University of Alberta; Edmonton, Alberta, Canada
| | - Norman M Kneteman
- Department of Surgery; University of Alberta; Edmonton, Alberta, Canada
| | - David Bigam
- Department of Surgery; University of Alberta; Edmonton, Alberta, Canada
| | - A M James Shapiro
- Department of Surgery; University of Alberta; Edmonton, Alberta, Canada
- Department of Medicine; University of Alberta; Edmonton, Alberta, Canada
- Canadian National Transplant Research Program (CNTRP); Edmonton, Alberta, Canada
| |
Collapse
|
26
|
Kashkoush S, El Moghazy W, Kawahara T, Gala-Lopez B, Toso C, Kneteman NM. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant 2014; 28:728-36. [DOI: 10.1111/ctr.12373] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/24/2014] [Indexed: 01/11/2023]
Affiliation(s)
- Samy Kashkoush
- Division of Transplantation; Department of Surgery; University of Alberta; Edmonton AB Canada
- Department of Surgery; National Liver Institute; Menofiya University; Menofiya Egypt
| | - Walid El Moghazy
- Division of Transplantation; Department of Surgery; University of Alberta; Edmonton AB Canada
- Department of Surgery; Sohag University; Sohag Egypt
| | - Toshiyasu Kawahara
- Division of Transplantation; Department of Surgery; University of Alberta; Edmonton AB Canada
| | - Boris Gala-Lopez
- Division of Transplantation; Department of Surgery; University of Alberta; Edmonton AB Canada
| | - Christian Toso
- Division of Transplantation; Department of Surgery; University of Alberta; Edmonton AB Canada
- Department of Visceral and Transplantation Surgery; University of Geneva; Geneva Switzerland
| | - Norman M. Kneteman
- Division of Transplantation; Department of Surgery; University of Alberta; Edmonton AB Canada
| |
Collapse
|
27
|
Cardoso FS, Karvellas CJ, Kneteman NM, Meeberg G, Fidalgo P, Bagshaw SM. Respiratory rate at intensive care unit discharge after liver transplant is an independent risk factor for intensive care unit readmission within the same hospital stay: a nested case-control study. J Crit Care 2014; 29:791-6. [PMID: 24857401 DOI: 10.1016/j.jcrc.2014.03.038] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 03/08/2014] [Accepted: 03/16/2014] [Indexed: 12/29/2022]
Abstract
PURPOSE Intensive care unit (ICU) readmission negatively impacts patients' outcomes. We aimed to characterize and determine risk factors for ICU readmission within the initial hospital stay after liver transplant (LT). MATERIALS AND METHODS The reference cohort included 369 LT recipients from a Canadian center between 2005 and 2012. One control was randomly selected per each case of ICU readmission within the initial hospital stay after LT. Survival analysis used the Kaplan-Meier method. Associations were studied by conditional logistic regression. RESULTS Fifty-two (14%) LT recipients were readmitted to the ICU within the initial hospital stay after LT; they had longer first hospital stay (P < .001) and lower 1-month to 2-year cumulative survival (P < .001). Respiratory failure was the major cause of ICU readmission (61%). Respiratory rate at discharge from the first ICU stay after LT was an independent risk factor for ICU readmission (odds ratio = 1.24). The cutoff point more than 20 breaths per minute prognosticated ICU readmission with a specificity of 90% and a positive predictive value of 80%. CONCLUSIONS Intensive care unit readmission within the initial hospital stay after LT negatively impacts LT recipients' outcomes. Monitoring respiratory rate at discharge from the first ICU stay after LT is important to prevent readmission.
Collapse
Affiliation(s)
- Filipe S Cardoso
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 3C1.12 Walter C Mackenzie Center, 8440-112 ST NW, Edmonton, Alberta, T6G-2B7, Canada.
| | - Constantine J Karvellas
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 3C1.12 Walter C Mackenzie Center, 8440-112 ST NW, Edmonton, Alberta, T6G-2B7, Canada; Division of Gastroenterology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, 130 University Campus NW, Edmonton, Alberta, T6G-2X8, Canada.
| | - Norman M Kneteman
- Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, T6G-2B7, Canada.
| | - Glenda Meeberg
- Liver Transplant Program, Alberta Health Services, Edmonton, Alberta, T6G-2B7, Canada.
| | - Pedro Fidalgo
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 3C1.12 Walter C Mackenzie Center, 8440-112 ST NW, Edmonton, Alberta, T6G-2B7, Canada.
| | - Sean M Bagshaw
- Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 3C1.12 Walter C Mackenzie Center, 8440-112 ST NW, Edmonton, Alberta, T6G-2B7, Canada.
| |
Collapse
|
28
|
Foster JR, Lund G, Sapelnikova S, Tyrrell DL, Kneteman NM. Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 2013; 44:109-22. [DOI: 10.3109/00498254.2013.867553] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
29
|
Robertson CMT, Dinu IA, Joffe AR, Alton GY, Yap JYK, Asthana S, Acton BV, Sauve RS, Martin SR, Kneteman NM, Gilmour SM. Neurocognitive outcomes at kindergarten entry after liver transplantation at <3 yr of age. Pediatr Transplant 2013; 17:621-30. [PMID: 23961979 DOI: 10.1111/petr.12134] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/11/2013] [Indexed: 12/22/2022]
Abstract
This prospective inception cohort study determines kindergarten-entry neurocognitive abilities and explores their predictors following liver transplantation at age <3 yr. Of 52 children transplanted (1999-2008), 33 (89.2%) of 37 eligible survivors had psychological assessment at age 54.7 (8.4) months: 21 with biliary atresia, seven chronic cholestasis, and five acute liver failure. Neurocognitive scores (mean [s.d.], 100 [15]) as tested by a pediatric-experienced psychologist did not differ in relation to age group at transplant (≤12 months and >12 months): FSIQ, 93.9 (17.1); verbal (VIQ), 95.3 (16.5); performance (PIQ), 94.3 (18.1); and VMI, 90.5 (15.9), with >70% having scores ≥85, average or above. Adverse predictors from the pretransplant, transplant, and post-transplant (30 days) periods using univariate linear regressions for FSIQ were post-transplant use of inotropes, p = 0.029; longer transplant warm ischemia time, p = 0.035; and post-transplant highest serum creatinine, (p = 0.04). For PIQ, they were pretransplant encephalopathy, p = 0.027; post-transplant highest serum creatinine, p = 0.034; and post-transplant inotrope use, p = 0.037. For VMI, they were number of post-transplant infections, p = 0.019; post-transplant highest serum creatinine, p = 0.025; and lower family socioeconomic index, p = 0.039. Changes in care addressing modifiable predictors, including reducing acute post-transplant illness, pretransplant encephalopathy, transplant warm ischemia times, and preserving renal function, may improve neurocognitive outcomes.
Collapse
Affiliation(s)
- Charlene M T Robertson
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; Pediatric Rehabilitation Outcomes Unit, Glenrose Rehabilitation Hospital, Edmonton, AB, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Kawahara T, Toso C, Yamaguchi K, Cader S, Douglas DN, Nourbakhsh M, Lewis JT, Churchill TA, Yagita H, Kneteman NM. Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma. Liver Int 2013; 33:1441-8. [PMID: 23895107 DOI: 10.1111/liv.12275] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 07/01/2013] [Indexed: 02/13/2023]
Abstract
BACKGROUND & AIMS Despite careful patient selection, hepatocellular carcinoma (HCC) recurs in 10-20% of cases after liver transplantation, and the use of potent adjuvant anticancer drugs would be welcome. The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti-death receptor (DR)5 monoclonal antibody (mAb) on HCC. METHODS We first assessed the side effects of anti-DR5 mAb administration in vivo by giving various doses of anti-DR5 mAb. Cell proliferation assays were then performed using mouse Hepa1-6 cells or human Huh7 cells to quantify the relative cell viability under various concentrations of sirolimus, anti-DR5 mAb or a combination. Next, one million Hepa1-6 cells were transplanted into C.B17-SCID-beige mice subcutaneously, and four groups were created: (1) untreated, (2) anti-DR5 mAb alone, (3) sirolimus alone and (4) anti-DR5 mAb + sirolimus. RESULTS Anti-DR5 mAb (200 and 300 μg/day) induced liver dysfunction with partial necrosis of the liver, but 100 μg/day was well tolerated with transaminitis, but normal bilirubin and only minor histological liver damage. In vitro, anti-DR5 mAb lysed Hepa1-6 and Huh7 cells in a dose-dependent manner, and combinations of sirolimus and anti-DR5 mAb demonstrated an additive effect. In vivo studies demonstrated that tumour sizes were significantly smaller in the combined therapy group than in the monotherapy groups. CONCLUSIONS Combining sirolimus and low-dose anti-DR5 mAb has a significant effect against HCC. This strategy represents a potential novel approach for the management of HCC.
Collapse
|
31
|
Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, Giostra E, Berney T, Morel P, Mentha G, Kneteman NM. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci 2013; 20:342-7. [PMID: 22710887 PMCID: PMC3590406 DOI: 10.1007/s00534-012-0528-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Although factors associated with an increased risk of recurrence after liver transplantation for hepatocellular carcinoma (HCC) have been extensively studied, the history of patients with a post-transplant recurrence is poorly known. METHODS Patients experiencing a post-transplant HCC recurrence from 1996 to 2011 in two transplant programs were included. Demographic, transplant, and post-recurrence variables were assessed. RESULTS Thirty patients experienced an HCC recurrence-22 men and 8 women with a mean age of 55 ± 6 years. Sixteen (53 %) were outside the Milan criteria at the time of transplantation. Most recurrences (60 %) appeared within the first 18 months after transplantation, ranging between 1.7 and 109 months (median 14.2 months). Mean post-recurrence survival was 33 ± 31 months. On univariate analysis, total tumor volume (TTV; p = 0.047), microvascular invasion (p = 0.011), and time from transplant to recurrence (p = 0.001) predicted post-recurrence survival. On multivariate analysis, both time from transplant to recurrence (p = 0.001) and history of rejection (p = 0.043), but not the location of the recurrence or the type of recurrence treatment, predicted post-recurrence survival. CONCLUSION This study suggests that patients with early post-transplant HCC recurrence have worse outcomes. Those with a history of graft rejection have better survivals, possibly due to more active anti-cancer immunity.
Collapse
Affiliation(s)
- Christian Toso
- Divisions of Transplant and Abdominal Surgery, Department of Surgery, University of Geneva Hospitals, Rue Gabrielle-Perret-Gentil, 1211, Geneva, Switzerland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, Giostra E, Berney T, Morel P, Mentha G, Kneteman NM. Erratum to: Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. Journal of Hepato-Biliary-Pancreatic Sciences 2013. [PMCID: PMC4079682 DOI: 10.1007/s00534-013-0618-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- Christian Toso
- Divisions of Transplant and Abdominal Surgery, Department of Surgery; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Sonia Cader
- Division of Transplantation, Department of Surgery; University of Alberta; 2D4.44 Mackenzie Center Edmonton AB T6G 2B7 Canada
| | - Ariane Mentha-Dugerdil
- Divisions of Transplant and Abdominal Surgery, Department of Surgery; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Glenda Meeberg
- Division of Transplantation, Department of Surgery; University of Alberta; 2D4.44 Mackenzie Center Edmonton AB T6G 2B7 Canada
| | - Pietro Majno
- Divisions of Transplant and Abdominal Surgery, Department of Surgery; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Isabelle Morard
- Division of Gastro-enterology, Department of Internal Medicine; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Emiliano Giostra
- Division of Gastro-enterology, Department of Internal Medicine; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Thierry Berney
- Divisions of Transplant and Abdominal Surgery, Department of Surgery; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Philippe Morel
- Divisions of Transplant and Abdominal Surgery, Department of Surgery; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Gilles Mentha
- Divisions of Transplant and Abdominal Surgery, Department of Surgery; University of Geneva Hospitals; Rue Gabrielle-Perret-Gentil 1211 Geneva Switzerland
| | - Norman M. Kneteman
- Division of Transplantation, Department of Surgery; University of Alberta; 2D4.44 Mackenzie Center Edmonton AB T6G 2B7 Canada
| |
Collapse
|
33
|
Kawahara T, Lisboa LF, Cader S, Douglas DN, Nourbakhsh M, Pu CH, Lewis JT, Churchill TA, Humar A, Kneteman NM. Human cytomegalovirus infection in humanized liver chimeric mice. Hepatol Res 2013; 43:679-84. [PMID: 23442000 DOI: 10.1111/j.1872-034x.2012.01116.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Revised: 10/02/2012] [Accepted: 10/04/2012] [Indexed: 02/08/2023]
Abstract
AIM Cytomegalovirus is a common viral pathogen that influences the outcome of organ transplantation. To date, there is no established method to evaluate the effects of human CMV (HCMV) treatments in vivo except for human clinical trials. In the current study, we describe the development of a mouse model that supports the in vivo propagation of HCMV. METHODS One million viable human hepatocytes, purified from human livers, were injected into the spleens of severe combined immunodeficient/albumin linked-urokinase type plasminogen activator transgenic mice. A clinical strain of HCMV was inoculated in mice with confirmed human hepatocyte engraftment or in non-chimeric controls. Infection was monitored through HCMV titers in the plasma. Mice were administrated ganciclovir (50 mg/kg per day, i.p.) beginning at 2 days post-HCMV inoculation, or human liver natural killer (NK) cells (20 × 10(6) cells/mouse, i.v.) 1 day prior to HCMV inoculation. RESULTS Chimeric mice that received HCMV showed high plasma titers of HCMV DNA on days 1 and 6 that became undetectable by day 11 post-inoculation. In contrast, non-transplanted mice had only residual plasma inoculum detection at day 1 and no detectable viremia thereafter. The levels of HCMV DNA were reduced by ganciclovir treatment or by human liver NK cell adoptive transfer, while HCMV-infected chimeric mice that were not treated sustained viremia during the follow up. CONCLUSION Human liver chimeric mice provide an in vivo model for the study of acute HCMV infection of hepatocytes.
Collapse
Affiliation(s)
- Toshiyasu Kawahara
- Division of Transplantation Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Karvellas CJ, Lescot T, Goldberg P, Sharpe MD, Ronco JJ, Renner EL, Vahidy H, Poonja Z, Chaudhury P, Kneteman NM, Selzner M, Cook EF, Bagshaw SM. Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study. Crit Care 2013; 17:R28. [PMID: 23394270 PMCID: PMC4056692 DOI: 10.1186/cc12508] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Accepted: 01/25/2013] [Indexed: 12/21/2022]
Abstract
Introduction Critically ill cirrhosis patients awaiting liver transplantation (LT) often receive prioritization for organ allocation. Identification of patients most likely to benefit is essential. The purpose of this study was to examine whether the Sequential Organ Failure Assessment (SOFA) score can predict 90-day mortality in critically ill recipients of LT and whether it can predict receipt of LT among critically ill cirrhosis listed awaiting LT. Methods We performed a multicenter retrospective cohort study consisting of two datasets: (a) all critically-ill cirrhosis patients requiring intensive care unit (ICU) admission before LT at five transplant centers in Canada from 2000 through 2009 (one site, 1990 through 2009), and (b) critically ill cirrhosis patients receiving LT from ICU (n = 115) and those listed but not receiving LT before death (n = 106) from two centers where complete data were available. Results In the first dataset, 198 critically ill cirrhosis patients receiving LT (mean (SD) age 53 (10) years, 66% male, median (IQR) model for end-stage liver disease (MELD) 34 (26-39)) were included. Mean (SD) SOFA scores at ICU admission, at 48 hours, and at LT were 12.5 (4), 13.0 (5), and 14.0 (4). Survival at 90 days was 84% (n = 166). In multivariable analysis, only older age was independently associated with reduced 90-day survival (odds ratio (OR), 1.07; 95% CI, 1.01 to 1.14; P = 0.013). SOFA score did not predict 90-day mortality at any time. In the second dataset, 47.9% (n = 106) of cirrhosis patients listed for LT died in the ICU waiting for LT. In multivariable analysis, higher SOFA at 48 hours after admission was independently associated with lower probability of receiving LT (OR, 0.89; 95% CI, 0.82 to 0.97; P = 0.006). When including serum lactate and SOFA at 48 hours in the final model, elevated lactate (at 48 hours) was also significantly associated with lower likelihood of receiving LT (0.32; 0.17 to 0.61; P = 0.001). Conclusions SOFA appears poor at predicting 90-day survival in critically ill cirrhosis patients after LT, but higher SOFA score and elevated lactate 48 hours after ICU admission are associated with a lower probability receiving LT. Older critically ill cirrhosis patients (older than 60) receiving LT have worse 90-day survival and should be considered for LT with caution.
Collapse
|
35
|
Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56:149-56. [PMID: 22271250 DOI: 10.1002/hep.25603] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Accepted: 01/02/2012] [Indexed: 02/06/2023]
Abstract
UNLABELLED In many countries, the allocation of liver grafts is based on the Model of End-stage Liver Disease (MELD) score and the use of exception points for patients with hepatocellular carcinoma (HCC). With this strategy, HCC patients have easier access to transplantation than non-HCC ones. In addition, this system does not allow for a dynamic assessment, which would be required to picture the current use of local tumor treatment. This study was based on the Scientific Registry of Transplant Recipients and included 5,498 adult candidates of a liver transplantation for HCC and 43,528 for non-HCC diagnoses. A proportional hazard competitive risk model was used. The risk of dropout of HCC patients was independently predicted by MELD score, HCC size, HCC number, and alpha-fetoprotein. When combined in a model with age and diagnosis, these factors allowed for the extrapolation of the risk of dropout. Because this model and MELD did not share compatible scales, a correlation between both models was computed according to the predicted risk of dropout, and drop-out equivalent MELD (deMELD) points were calculated. CONCLUSION The proposed model, with the allocation of deMELD, has the potential to allow for a dynamic and combined comparison of opportunities to receive a graft for HCC and non-HCC patients on a common waiting list.
Collapse
Affiliation(s)
- Christian Toso
- Division of Transplant, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Wu X, Robotham JM, Lee E, Dalton S, Kneteman NM, Gilbert DM, Tang H. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012; 8:e1002617. [PMID: 22496645 PMCID: PMC3320597 DOI: 10.1371/journal.ppat.1002617] [Citation(s) in RCA: 144] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2011] [Accepted: 02/17/2012] [Indexed: 01/14/2023] Open
Abstract
Primary human hepatocytes isolated from patient biopsies represent the most physiologically relevant cell culture model for hepatitis C virus (HCV) infection, but these primary cells are not readily accessible, display individual variability, and are largely refractory to genetic manipulation. Hepatocyte-like cells differentiated from pluripotent stem cells provide an attractive alternative as they not only overcome these shortcomings but can also provide an unlimited source of noncancer cells for both research and cell therapy. Despite its promise, the permissiveness to HCV infection of differentiated human hepatocyte-like cells (DHHs) has not been explored. Here we report a novel infection model based on DHHs derived from human embryonic (hESCs) and induced pluripotent stem cells (iPSCs). DHHs generated in chemically defined media under feeder-free conditions were subjected to infection by both HCV derived in cell culture (HCVcc) and patient-derived virus (HCVser). Pluripotent stem cells and definitive endoderm were not permissive for HCV infection whereas hepatic progenitor cells were persistently infected and secreted infectious particles into culture medium. Permissiveness to infection was correlated with induction of the liver-specific microRNA-122 and modulation of cellular factors that affect HCV replication. RNA interference directed toward essential cellular cofactors in stem cells resulted in HCV-resistant hepatocyte-like cells after differentiation. The ability to infect cultured cells directly with HCV patient serum, to study defined stages of viral permissiveness, and to produce genetically modified cells with desired phenotypes all have broad significance for host-pathogen interactions and cell therapy. Physiologically relevant cell-culture models for infection with hepatitis C virus (HCV) are scarce, and infection by viruses derived from patient serum has been inefficient. Differentiated human hepatocyte-like cells derived from pluripotent stem cells demonstrate hepatic functions but have not been explored for HCV infection studies. Here we report a novel infection model based on these hepatocyte-like cells. Stem cells and definitive endoderm successfully resisted HCV infection, whereas hepatic progenitor cells derived from the stem cells were productively infected by both human- and cell-culture-derived HCV. We determined the point of transition from resistance to susceptibility and, by comparative gene profiling, identified the host factors that were correlated with susceptibility. Genetic modification of human embryonic stem cells, coupled with hepatic differentiation, generated hepatocyte-like cells that were resistant to HCV infection. Our study establishes a new noncancerous and renewable cell-culture system for HCV infection, permits direct infection of cells by patient sera in vitro, identifies a defined transition to HCV susceptibility during hepatocyte differentiation, and demonstrates the feasibility of generating virus-resistant human hepatocyte-like cells in vitro.
Collapse
Affiliation(s)
- Xianfang Wu
- Department of Biological Science, Florida State University, Tallahassee, Florida, United States of America
| | - Jason M. Robotham
- Department of Biological Science, Florida State University, Tallahassee, Florida, United States of America
| | - Emily Lee
- Department of Biological Science, Florida State University, Tallahassee, Florida, United States of America
| | - Stephen Dalton
- Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia, United States of America
| | - Norman M. Kneteman
- Division of Transplantation, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - David M. Gilbert
- Department of Biological Science, Florida State University, Tallahassee, Florida, United States of America
| | - Hengli Tang
- Department of Biological Science, Florida State University, Tallahassee, Florida, United States of America
- * E-mail:
| |
Collapse
|
37
|
Kneteman NM, Asthana S, Lewis J, Dibben C, Douglas D, Nourbakhsh M, Tyrrell LJ, Lund G. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection. Liver Transpl 2012; 18:38-44. [PMID: 21837737 DOI: 10.1002/lt.22400] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Cyclosporine A (CSA) has potent effects against hepatitis C virus (HCV) in vitro, but its clinical efficacy after liver transplantation (LT) is uncertain. We evaluated the impact of CSA and tacrolimus (TAC) with or without concomitant interferon (IFN) therapy on serum HCV titers in a chimeric mouse model of HCV infection. Six groups of HCV-infected mice received only the vehicle, IFN, CSA, CSA and IFN, TAC, or TAC and IFN for 4 weeks. The quantitative HCV polymerase chain reaction levels were determined after 1, 2, and 4 weeks of drug administration. There were no significant differences in the HCV titers after 4 weeks of treatment between the non-IFN-treated groups (log HCV titers: 3.5 ± 0.3 for the vehicle group, 4.4 ± 0.6 for the CSA group, and 4.3 ± 0.4 for the TAC group, P = 0.3). Although IFN had a consistent effect of reducing HCV titers across the groups, there was no significant impact of CSA on HCV levels when it was used alone or in combination with IFN at any time point. The 4-week HCV titers were as follows: 3.2 ± 0.3 for the IFN group, 4.7 ± 0.4 for the CSA/IFN group, and 4.0 ± 0.5 for the TAC/IFN group (P = 0.07). The CSA/IFN and TAC/IFN groups did not differ significantly (P = 0.6). Six of the 7 animals in the IFN group (85.7%) had an HCV titer decline ≥ 1 log, whereas in the test groups (CSA/IFN and TAC/IFN), 6 of 9 animals (66.7%) achieved a 1-log decline in the HCV titer (P = 1). Using this animal model, we could find no evidence supporting the routine use of CSA after LT in HCV-infected patients.
Collapse
Affiliation(s)
- Norman M Kneteman
- Division of Transplantation, Department of Surgery, University of Alberta, 8440 112 Street NW, Edmonton, AB, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Kawahara T, Kin T, Kashkoush S, Gala-Lopez B, Bigam DL, Kneteman NM, Koh A, Senior PA, Shapiro AJ. Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am J Transplant 2011; 11:2700-7. [PMID: 21883914 PMCID: PMC3226916 DOI: 10.1111/j.1600-6143.2011.03717.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Percutaneous transhepatic portal access avoids surgery but is rarely associated with bleeding or portal venous thrombosis (PVT). We herein report our large, single-center experience of percutaneous islet implantation and evaluate risk factors of PVT and graft function. Prospective data were collected on 268 intraportal islet transplants (122 subjects). A portal venous Doppler ultrasound was obtained on Days 1 and 7 posttransplant. Therapeutic heparinization, complete ablation of the portal catheter tract with Avitene paste and limiting packed cell volume (PCV) to <5 mL completely prevented any portal thrombosis in the most recent 101 islet transplant procedures over the past 5 years. In the previous cumulative experience, partial thrombosis did not affect islet function. Standard liver volume correlated negatively (r =-0.257, p < 0.001) and PCV correlated positively with portal pressure rise (r = 0.463, p < 0.001). Overall, partial portal thrombosis occurred after 10 procedures (overall incidence 3.7%, most recent 101 patient incidence 0%). There were no cases of complete thrombosis and no patient developed sequelae of portal hypertension. In conclusion, portal thrombosis is a preventable complication in clinical islet transplantation, provided therapeutic anticoagulation is maintained and PCV is limited to <5 mL.
Collapse
Affiliation(s)
| | - Tatsuya Kin
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Samy Kashkoush
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - Boris Gala-Lopez
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | - David L. Bigam
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
| | | | - Angela Koh
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | - Peter A. Senior
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
| | | |
Collapse
|
39
|
Abstract
The development of calcineurin inhibitors (CNIs) led to marked improvements in patient and graft survival after liver transplantation (LTx). We have been left, however, with a dependence on immunosuppressive agents with nephrotoxicity, neurotoxicity, adverse impacts on cardiac risk profile, and risk for malignancy. These challenges need to be met against a dominance of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) as indications for liver transplant. Unmet needs for immunosuppression (IS) in LTx include: (1) Effective drugs that avoid CNIs toxicities. (2) Agents without adverse impact on HCV recurrence. (3) Compounds that minimize risk of HCC recurrence. New immunosuppressives will need to address the above needs while supporting patient and graft survival equivalent to those achievable with CNIs, ideally without important new toxicities. Two new classes of agents are currently in advanced clinical development: belatacept, and the mammalian target of rapamycin inhibitors (m-TORi). This manuscript will review evidence for a role for m-TORi in LTx in a range of clinical scenarios including patients with CNI nephrotoxicity or neurotoxicity, patients at risk of (or with) HCV recurrence, and patients at risk of HCC recurrence.
Collapse
Affiliation(s)
- Toshiyasu Kawahara
- Division of Transplantation, Department of Surgery, University of Alberta, Canada
| | | | | |
Collapse
|
40
|
Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55:814-9. [PMID: 21334400 DOI: 10.1016/j.jhep.2010.12.040] [Citation(s) in RCA: 143] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Revised: 11/20/2010] [Accepted: 12/22/2010] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Liver transplantation is a recognized treatment for selected patients with hepatocellular carcinoma (HCC), but transplant criteria still need to be refined, especially in the case of more advanced or downstaged tumors. METHODS The present study investigated alpha-fetoprotein (AFP) as a predictor of outcome in 6817 patients listed with a diagnosis of HCC in the Scientific Registry of Transplant Recipients. RESULTS Local pre-transplant HCC treatment was used in 41% of patients on the waiting list. Patients with AFP levels>400 ng/ml at the time of listing who were downstaged to AFP ≤400 ng/ml had better intent-to-treat survival than patients failing to reduce AFP to ≤400 (81% vs. 48% at 3 years, p ≤0.001) and comparable survival to patients with stable AFP ≤400 ng/ml (74%, p = 0.14). Patients with AFP levels decreased ≤400 ng/ml and patients with levels persistently ≤400 ng/ml also had similar drop-out rates from the list (10% in both groups) and post-transplant survival rates (89% vs. 78% at 3 years, p = 0.11). Such an AFP downstaging was associated with good survivals whatever the level of the original AFP (even if originally>1000 ng/ml). Only the last pre-transplant AFP independently predicted survival (p ≤0.001), unlike AFP at listing or AFP changes. CONCLUSIONS Overall, downstaging HCC patients with high AFP is feasible and leads to similar intent-to-treat and post-transplant survivals to those of patients with AFP persistently low. Only last AFP appears relevant for patient selection before transplantation and should be used in combination with morphological variables.
Collapse
Affiliation(s)
- Shaheed Merani
- Department of Surgery, University of Alberta, Edmonton, Canada
| | | | | | | | | | | | | |
Collapse
|
41
|
Mohajerani SA, Nourbakhsh M, Cadili A, Lakey JR, Kneteman NM. Transplant of Primary Human Hepatocytes Cocultured With Bone Marrow Stromal Cells to SCID Alb-uPA Mice. Cell Med 2010; 1:81-92. [PMID: 26966632 DOI: 10.3727/215517910x536627] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Hepatocytes are vulnerable to loss of function and viability in culture. Modified culture methods have been applied to maintain their functional status. Heterotypic interactions between hepatocytes and nonparenchymal neighbors in liver milieu are thought to modulate cell differentiation. Cocultivation of hepatocyte with various cell types has been applied to mimic the hepatic environment. Bone marrow stromal cells (BMSC) are plastic cell lines capable of transforming to other cell types. In this study hepatocyte coculture with BMSCs achieved long-term function of human hepatocytes in culture for 4 weeks. In vitro functional status of human hepatocytes in BMSC coculture was compared with fibroblast coculture and collagen culture by measuring albumin, human-α-1-antitrypsin (hAAT), urea secretion, CYP450 activity, and staining for intracellular albumin and glycogen. After 2 weeks in culture hepatocytes were retrieved and transplanted to severe combined immunodeficiency/albumin linked-urokinase type plasminogen activator (SCID Alb-uPA) mice and engraft-ment capacity was analyzed by human hepatic-specific function measured by hAAT levels in mouse serum, and Alu staining of mouse liver for human hepatocytes. Hepatocytes from BMSC coculture had significantly higher albumin, hAAT secretion, urea production, and cytochrome P450 (CYP450) activity than other culture groups. Staining confirmed the higher functional status in BMSC coculture. Transplantation of hepatocytes detached from BMSC cocultures showed significantly higher engraftment function than hepatocytes from other culture groups measured by hAAT levels in mouse serum. In conclusion, BMSC coculture has excellent potential for hepatocyte function preservation in vitro and in vivo after transplant. It is possible to use BMSC hepatocyte coculture as a supply of cell therapy in liver disease.
Collapse
Affiliation(s)
- S A Mohajerani
- Department of Surgery, University of Alberta , Edmonton, Alberta , Canada
| | - M Nourbakhsh
- Department of Surgery, University of Alberta , Edmonton, Alberta , Canada
| | - A Cadili
- Department of Surgery, University of Alberta , Edmonton, Alberta , Canada
| | - J R Lakey
- † Division of Surgical Research, Department of Surgery, University of California , Irvine, CA , USA
| | - N M Kneteman
- Department of Surgery, University of Alberta , Edmonton, Alberta , Canada
| |
Collapse
|
42
|
Steenbergen RHG, Joyce MA, Lund G, Lewis J, Chen R, Barsby N, Douglas D, Zhu LF, Tyrrell DL, Kneteman NM, Kneteman NM. Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success. Am J Physiol Gastrointest Liver Physiol 2010; 299:G844-54. [PMID: 20651006 DOI: 10.1152/ajpgi.00200.2010] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Although multiple determinants for hepatitis C virus (HCV) infection are known, it remains partly unclear what determines the human specificity of HCV infection. Presumably, the presence of appropriate entry receptors is essential, and this may explain why HCV is unable to infect nonhuman hepatocytes. However, using mice with chimeric human livers, we show in this study that the presence of human hepatocytes, and therefore human entry receptors, is not sufficient for HCV infection. In successfully transplanted SCID/Alb-uPA mice, infection with HCV is reliable only when ∼70-80% of the liver consists of human hepatocytes. We show that chimeric mice, which are hard to infect with HCV, have significant groups of human hepatocytes that are readily infected with hepatitis B virus. Thus it is unlikely that the lack of infection with HCV can simply be attributed to low hepatocyte numbers. We investigated whether the humanization of lipoprotein profiles is positively associated with infection success. We show that the lipoprotein profiles of chimeric mice become more human-like at high levels of engraftment of human hepatocytes. This and expression of markers of human lipoprotein biosynthesis, human apolipoprotein B (ApoB) and cholesterol ester transfer protein (CETP), show a strong positive correlation with successful infection. Association of HCV in the blood of chimeric mice to ApoB-containing lipoproteins is comparable to association of HCV in patient serum and provides further support for a critical role for ApoB-containing lipoproteins in the infectious cycle of HCV. Our data suggest that the weakest link in the HCV infection chain does not appear to be the presence of human hepatocytes per se. We believe that HCV infection also depends on the presence of sufficient levels of human lipoproteins.
Collapse
Affiliation(s)
- Rineke H G Steenbergen
- Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology,Katz Centre for Pharmacy and Health Research,National Canadian Research Training Program in Hepatitis C, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Hopital Saint-Luc, Montreal, Quebec, Canada.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Kawahara T, Toso C, Douglas DN, Nourbakhsh M, Lewis JT, Tyrrell DL, Lund GA, Churchill TA, Kneteman NM. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl 2010; 16:974-82. [PMID: 20677288 DOI: 10.1002/lt.22099] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Human hepatocyte transplantation is an alternative treatment for acute liver failure and liver diseases involving enzyme deficiencies. Although it has been successfully applied in selected recipients, both isolation and transplantation outcomes have the potential to be improved by better donor selection. This study assessed the impact of various donor variables on isolation outcomes (yield and viability) and posttransplant engraftment, using the SCID/Alb-uPA (severe combined immunodeficient/urokinase type plasminogen activator under the control of an albumin promoter) human liver chimeric mouse model. Human hepatocytes were obtained from 90 human liver donor specimens and were transplanted into 3942 mice. Multivariate analysis revealed improved viability with younger donors (P = 0.038) as well as with shorter warm ischemic time (P = 0.012). Hepatocyte engraftment, assessed by the posttransplant level of serum human alpha1-antitrypsin, was improved with shorter warm ischemia time. Hepatocytes isolated from older donors (>or=60 years) had lower viability and posttransplant engraftment (P <or= 0.01). In conclusion, the selection of young donors (<60 years) and rapid liver specimen retrieval, allowing for shorter warm ischemia time, are key determinants for the success of both the isolation of high viability human hepatocytes and their subsequent posttransplantation capacity for engraftment and expansion.
Collapse
|
44
|
Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol 2010; 52:930-6. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2009] [Revised: 12/14/2009] [Accepted: 12/14/2009] [Indexed: 02/06/2023]
Abstract
In the treatment of hepatocellular carcinomas, therapies such as trans-arterial chemo-embolisation, trans-arterial radioembolisation, percutaneous ethanol injection and radio-frequency ablation can decrease the size (and overall viability) of the tumours, thus potentially increasing the proportion of patients qualifying for resection and transplantation. While the use of such downstaging therapies is straightforward when resection is the aim, in a similar way to other neo-adjuvant treatments in the surgery of tumours that are too large or awkwardly placed to be primarily resected the issues related to transplantation are more complex. In the context of transplantation the word "downstaging" designates not only a neo-adjuvant treatment, but also a selection strategy to allow patients who are initially outside accepted listing criteria to benefit from transplantation should the neo-adjuvant therapy be successful in reducing tumour burden. The effectiveness of downstaging as a selection strategy, at first questioned because of methodological bias in the studies that described it, has been recently demonstrated by more solid prospective investigations. Several issues however remain open, such as inclusion criteria before the strategy is implemented (size/number, surrogate markers of differentiation/vascular invasion such as alpha-fetoprotein), the choice of which downstaging therapy, the end-points of treatment, and the need and duration of a period of observation proving disease response or stabilisation before the patient can be listed. The present review discusses which treatments and strategies are available for downstaging HCC on the basis of the published literature.
Collapse
Affiliation(s)
- Christian Toso
- Transplantation Unit, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland.
| | | | | | | |
Collapse
|
45
|
Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10:190. [PMID: 20459775 PMCID: PMC2889889 DOI: 10.1186/1471-2407-10-190] [Citation(s) in RCA: 133] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2009] [Accepted: 05/11/2010] [Indexed: 11/25/2022] Open
Abstract
Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods/Design The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 21/2 -year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. Trial Register Trial registered at http://www.clinicaltrials.gov: NCT00355862 (EudraCT Number: 2005-005362-36)
Collapse
|
46
|
Toso C, Merani S, Bigam DL, Shapiro AMJ, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51:1237-43. [PMID: 20187107 DOI: 10.1002/hep.23437] [Citation(s) in RCA: 237] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
UNLABELLED Liver transplantation is an important treatment option for selected patients with nonresectable hepatocellular carcinoma (HCC). Several reports have suggested a lower risk of posttransplant tumor recurrence with the use of sirolimus and a higher one with calcineurin inhibitors, but the selection of an ideal immunosuppression protocol is still a matter of debate. The aim of this study was to define the immunosuppression associated with the best survival after liver transplantation for HCC. It was based on the Scientific Registry of Transplant Recipients and included 2,491 adult recipients of isolated liver transplantation for HCC and 12,167 for non-HCC diagnoses between March 2002 and March 2009. All patients remained on stable maintenance immunosuppression protocols for at least 6 months posttransplant. In a multivariate analysis, only anti-CD25 antibody induction and sirolimus-based maintenance therapy were associated with improved survivals after transplantation for HCC (hazard ratio [HR] 0.64, 95% confidence interval [CI]: 0.45-0.9, P < or = 0.01; HR 0.53, 95% CI: 0.31-0.92, P < or = 0.05, respectively). The other studied drugs, including calcineurin inhibitors, did not demonstrate a significant impact. In an effort to understand whether the observed effects were due to a direct impact of the drug on tumor or more on liver transplant in general, we conducted a similar analysis on non-HCC patients. Although anti-CD25 induction was again associated with a trend toward improved survival, sirolimus showed a trend toward lower rates of survival in non-HCC recipients, confirming the specificity of its beneficial impact to cancer patients. CONCLUSION According to these data, sirolimus-based immunosuppression has unique posttransplant effects on HCC patients that lead to improved survival.
Collapse
Affiliation(s)
- Christian Toso
- Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada.
| | | | | | | | | |
Collapse
|
47
|
Kawahara T, Douglas DN, Lewis J, Lund G, Addison W, Tyrrell DL, Churchill TA, Kneteman NM. Critical role of natural killer cells in the rejection of human hepatocytes after xenotransplantation into immunodeficient mice. Transpl Int 2010; 23:934-43. [PMID: 20180929 DOI: 10.1111/j.1432-2277.2010.01063.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The severe combined immunodeficiency/albumin linked-urokinase type plasminogen activator (SCID/Alb-uPA) human liver chimeric mouse model has added a new dimension to studies of liver based human diseases and has important potential for study of human hepatic drug metabolism. However, it remains unclear if natural killer (NK) cell in SCID/Alb-uPA mice has an important negative impact on engraftment and expansion of human hepatocytes after transplantation. Here, we explore the role of mouse NK cells in the rejection of transplanted human hepatocytes in SCID/Alb-uPA mice. We assessed NK cell activity in vivo, using (125)I-iodo-2'-deoxyuridine incorporation assay. Low serum human alpha-1 antitrypsin (hAAT, <10 microg/ml) recipients, representing graft failure, showed resistance to engraftment of MHC class I knockout marrow (indicating high NK cell activity), while NK cell-depleted low hAAT recipients and high hAAT (>100 microg/ml) recipients accepted MHC class I knockout marrow, indicating a correlation between low NK cell activity, in vivo, and high level human hepatocyte engraftment. We also showed that higher level engraftment of human hepatocytes was achieved in both NK cell-depleted SCID/Alb-uPA mice and Rag2(-/-)gammac(-/-)/Alb-uPA (T,B and NK cell deficient) mice compared with untreated SCID/Alb-uPA mice. These results support a critical role for mouse NK cells in the rejection of human hepatocytes xenotransplanted to immunodeficient mice.
Collapse
|
48
|
Abstract
Estimates of hepatitis C virus infection include 170 million people worldwide, who face increased risk of development of cirrhosis, liver failure, and hepatocellular carcinoma. Standard of care therapy with pegylated interferon and ribavirin is effective in just half of patients, is challenged by substantial treatment-related morbidity, and is prohibitively expensive in most parts of the world. New therapeutics for treatment and prevention are clearly needed. Development of effective therapies has been significantly hampered by difficulties in establishing in vitro and in vivo models of viral replication. This chapter reviews development, validation, and early application of a mouse model with a chimeric human liver.
Collapse
Affiliation(s)
- Norman M Kneteman
- Department of Surgery Faculty of Medicine and Oral Health Sciences, University of Alberta, Edmonton, Canada
| | | |
Collapse
|
49
|
Wang P, Lo A, Young JB, Song JH, Lai R, Kneteman NM, Hao C, Li L. Targeted Quantitative Mass Spectrometric Identification of Differentially Expressed Proteins between Bax-Expressing and Deficient Colorectal Carcinoma Cells. J Proteome Res 2009; 8:3403-14. [DOI: 10.1021/pr9000477] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Peng Wang
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - Andy Lo
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - J. Bryce Young
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - Jin H. Song
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - Raymond Lai
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - Norman M. Kneteman
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - Chunhai Hao
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| | - Liang Li
- Departments of Chemistry, Laboratory Medicine & Pathology and Surgery, University of Alberta, Edmonton, Alberta T6G 2G2, Canada, and Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322
| |
Collapse
|
50
|
Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009; 22:869-75. [PMID: 19386075 DOI: 10.1111/j.1432-2277.2009.00882.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Recently, several groups have introduced expanded criteria for selection of patients with hepatocellular carcinoma (HCC) prior to transplant, but the exact number of potential newly recruited patients remains unclear. This registry-based study assessed 270 patients diagnosed with HCC. The potential number of transplant candidates was based on age (< or =65 years), absence of metastases and macro-vascular invasion, and on 12 previously published, expanded selection criteria. A wide range of increase in the number of transplant candidates was observed (12-63% when compared with the number of such candidates who would have been selected solely based on the Milan criteria). The most conservative criteria were Seoul (Kwon, 2007; increase of 12%), Valencia (Silva, 2008; 16%), total tumor volume/alpha-fetoprotein (Toso, 2009; 20%) and UCSF (Yao, 2007; 20%). This data will assist Centers and policy agencies in predicting the need for resources linked to an expansion of criteria.
Collapse
Affiliation(s)
- Christian Toso
- Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, AB, Canada.
| | | | | | | |
Collapse
|